
<html lang="en"     class="pb-page"  data-request-id="139bf6b4-27a2-41e7-b087-338988c9983e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm9014982;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2010.53.issue-2"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402" /></meta><meta name="dc.Creator" content="Christoph M.  Dehnhardt" /></meta><meta name="dc.Creator" content="Aranapakam M.  Venkatesan" /></meta><meta name="dc.Creator" content="Efren  Delos Santos" /></meta><meta name="dc.Creator" content="Zecheng  Chen" /></meta><meta name="dc.Creator" content="Osvaldo  Santos" /></meta><meta name="dc.Creator" content="Semiramis  Ayral-Kaloustian" /></meta><meta name="dc.Creator" content="Natasja  Brooijmans" /></meta><meta name="dc.Creator" content="Robert  Mallon" /></meta><meta name="dc.Creator" content="Irwin  Hollander" /></meta><meta name="dc.Creator" content="Larry  Feldberg" /></meta><meta name="dc.Creator" content="Judy  Lucas" /></meta><meta name="dc.Creator" content="Inder  Chaudhary" /></meta><meta name="dc.Creator" content="Ker  Yu" /></meta><meta name="dc.Creator" content="Jay  Gibbons" /></meta><meta name="dc.Creator" content="Robert  Abraham" /></meta><meta name="dc.Creator" content="Tarek S.  Mansour" /></meta><meta name="dc.Description" content="Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of 3 (PKI-402). Compound 3 exhibi..." /></meta><meta name="Description" content="Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of 3 (PKI-402). Compound 3 exhibi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 7, 2009" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm9014982" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2009 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm9014982" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm9014982" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm9014982" /></link>
        
    
    

<title>Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm9014982" /></meta><meta property="og:title" content="Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0001.jpeg" /></meta><meta property="og:description" content="Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of 3 (PKI-402). Compound 3 exhibits good physical properties and PK parameters, low nanomolar potency against PI3Kα and mTOR, and excellent inhibition of cell proliferation in several human cancer cell lines. Furthermore, in vitro and in vivo biomarker studies demonstrated the ability of 3 to shut down the PI3K/Akt pathway and induce apoptosis in cancer cells. In addition, 3 showed excellent in vivo efficacy in various human cancer xenografts, validating suppression of PI3K/mTOR signaling as a potential anticancer therapy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm9014982"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm9014982">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm9014982&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm9014982&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm9014982&amp;href=/doi/10.1021/jm9014982" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 798-810</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm901457w" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm901540n" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christoph+M.++Dehnhardt">Christoph M. Dehnhardt</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aranapakam+M.++Venkatesan">Aranapakam M. Venkatesan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Efren++Delos+Santos">Efren Delos Santos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zecheng++Chen">Zecheng Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Osvaldo++Santos">Osvaldo Santos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Semiramis++Ayral-Kaloustian">Semiramis Ayral-Kaloustian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Natasja++Brooijmans">Natasja Brooijmans</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Mallon">Robert Mallon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Irwin++Hollander">Irwin Hollander</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Larry++Feldberg">Larry Feldberg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Judy++Lucas">Judy Lucas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Inder++Chaudhary">Inder Chaudhary</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ker++Yu">Ker Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jay++Gibbons">Jay Gibbons</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Abraham">Robert Abraham</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tarek+S.++Mansour">Tarek S. Mansour</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Discovery Medicinal Chemistry</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Computational Chemistry</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Oncology</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Drug Safety and Metabolism</span></div><div class="aff-info" id="wr"><span class="aff-text">Wyeth Research, Pearl River, New York 10965</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: 1-845-602-2146. Fax: 1-845-602-5561. E-mail: <a href="/cdn-cgi/l/email-protection#197d7c717771787a596e607c6d71377a7674"><span class="__cf_email__" data-cfemail="4723222f292f262407303e22332f6924282a">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm9014982&amp;href=/doi/10.1021%2Fjm9014982" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 798–810</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 7, 2009</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 October 2009</li><li><span class="item_label"><b>Published</b> online</span>7 December 2009</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 January 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm9014982" title="DOI URL">https://doi.org/10.1021/jm9014982</a></div><div class="article_header-article-copyright"><strong>Copyright © 2009 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D798%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChristoph%2BM.%2BDehnhardt%252C%2BAranapakam%2BM.%2BVenkatesan%252C%2BEfren%2BDelos%2BSantos%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D2%26contentID%3Djm9014982%26title%3DLead%2BOptimization%2Bof%2BN-3-Substituted%2B7-Morpholinotriazolopyrimidines%2Bas%2BDual%2BPhosphoinositide%2B3-Kinase%252FMammalian%2BTarget%2Bof%2BRapamycin%2BInhibitors%253A%2BDiscovery%2Bof%2BPKI-402%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D810%26publicationDate%3DJanuary%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm9014982"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3617</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">50</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm9014982" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Christoph&quot;,&quot;last_name&quot;:&quot;M. Dehnhardt&quot;},{&quot;first_name&quot;:&quot;Aranapakam&quot;,&quot;last_name&quot;:&quot;M. Venkatesan&quot;},{&quot;first_name&quot;:&quot;Efren&quot;,&quot;last_name&quot;:&quot;Delos Santos&quot;},{&quot;first_name&quot;:&quot;Zecheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Osvaldo&quot;,&quot;last_name&quot;:&quot;Santos&quot;},{&quot;first_name&quot;:&quot;Semiramis&quot;,&quot;last_name&quot;:&quot;Ayral-Kaloustian&quot;},{&quot;first_name&quot;:&quot;Natasja&quot;,&quot;last_name&quot;:&quot;Brooijmans&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Mallon&quot;},{&quot;first_name&quot;:&quot;Irwin&quot;,&quot;last_name&quot;:&quot;Hollander&quot;},{&quot;first_name&quot;:&quot;Larry&quot;,&quot;last_name&quot;:&quot;Feldberg&quot;},{&quot;first_name&quot;:&quot;Judy&quot;,&quot;last_name&quot;:&quot;Lucas&quot;},{&quot;first_name&quot;:&quot;Inder&quot;,&quot;last_name&quot;:&quot;Chaudhary&quot;},{&quot;first_name&quot;:&quot;Ker&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Jay&quot;,&quot;last_name&quot;:&quot;Gibbons&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Abraham&quot;},{&quot;first_name&quot;:&quot;Tarek&quot;,&quot;last_name&quot;:&quot;S. Mansour&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2009&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;798-810&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm9014982&quot;},&quot;abstract&quot;:&quot;Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of 3 (PKI-402). Compound 3 exhibits good physical properties and PK parameters, low nanomolar potency against PI3Kα and mTOR, and excellent inhibition of cell proliferation in several human cancer cell lines. Furthermore, in vitro and in vivo biomarker studies demonstrated the ability of 3 to shut down the PI3K/Akt pathway and induce apoptosis in cancer cells. In addition, 3 showed excellent in vivo efficacy in various human cancer xenografts, validating suppression of PI3K/mTOR signaling as a potential anticancer therapy.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm9014982&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9014982" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm9014982&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9014982" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm9014982&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9014982" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm9014982&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9014982&amp;href=/doi/10.1021/jm9014982" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm9014982" /></input><a href="/doi/pdf/10.1021/jm9014982" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm9014982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm9014982%26sid%3Dliteratum%253Aachs%26pmid%3D19968288%26genre%3Darticle%26aulast%3DDehnhardt%26date%3D2010%26atitle%3DLead%2BOptimization%2Bof%2BN-3-Substituted%2B7-Morpholinotriazolopyrimidines%2Bas%2BDual%2BPhosphoinositide%2B3-Kinase%252FMammalian%2BTarget%2Bof%2BRapamycin%2BInhibitors%253A%2BDiscovery%2Bof%2BPKI-402%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D2%26spage%3D798%26epage%3D810%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292602" title="Biomarkers">Biomarkers</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of <b>3</b> (PKI-402). Compound <b>3</b> exhibits good physical properties and PK parameters, low nanomolar potency against PI3Kα and mTOR, and excellent inhibition of cell proliferation in several human cancer cell lines. Furthermore, in vitro and in vivo biomarker studies demonstrated the ability of <b>3</b> to shut down the PI3K/Akt pathway and induce apoptosis in cancer cells. In addition, <b>3</b> showed excellent in vivo efficacy in various human cancer xenografts, validating suppression of PI3K/mTOR signaling as a potential anticancer therapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The phosphoinositide 3-kinases (PI3K<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a>) <div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: PI3K, phosphoinositide 3-kinase; mTOR, mammalian target of rapamycin; Akt, protein kinase B; PIP2, phosphatidylinositol bisphosphate (4,5); PIP3, phosphatidylinositol triphosphate (3,4,5); PTEN, phosphatase and tensin homologue; RTK, receptor tyrosine kinase; PH, pleckstrin homology; mTORC1, mammalian target of rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; PDK1, 3-phosphoinositide-dependent kinase 1; S, serine; T, threonine; ATP, adenosine 5′-triphosphate; Her2+, human epidermal growth factor receptor 2+; ELISA, enzyme-linked immunosorbent assay; DELFIA, dissociation-enhanced lanthanide fluorescent.</p></div> are a group of enzymes that phosphorylate the 3′-OH position of the inositol ring of phosphatidylinositol bisphosphate (4,5) (PIP2) to phosphatidylinositol triphosphate (3,4,5) (PIP3). Class I PI3Ks are divided into two groups, class IA (p110α, P110β, and p110δ isoforms) and class IB (p110γ). These isoforms are structurally similar but differ in subunit association and mode of activation (e.g., receptor tyrosine kinase vs G-protein-coupled receptor). Aberrant PI3K signaling caused by phosphoinositide 3-kinase α encoded gene (PIKCA) amplification or mutation, PIK3R1 mutation, phosphatase and tensin homologue (PTEN) loss, or receptor tyrosine kinase (RTK) dependent activation occurs in about 50% of all known solid tumors. Deregulated PI3K activity leads to elevated levels of PIP3, which acts as a second messenger responsible for the activation of the downstream kinase protein kinase B (Akt).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> PIP3 is bound by the PH (pleckstrin homology) domains of both PDK1 and Akt serine/threonine (S/T) kinases resulting in their proximity at the inner cell membrane where 3-phosphoinositide-dependent kinase 1 (PDK1) phosphorylates and activates Akt (at T308).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Aberrantly activated Akt promotes growth, survival, proliferation, enhanced migration, and adhesion in cancer cells. Many Akt effects are mediated through the S/T kinase mammalian target of rapamycin (mTOR), which exists as either the mTOR complex-1 (TORC1) or mTOR complex-2 (TORC2) enzyme complexes. TORC1 regulates such processes as protein biosynthesis, while TORC2 fully activates Akt kinase by phosphorylating it at serine 473 (S473).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> A dual PI3K/mTOR inhibitor could both prevent cancer cell proliferation and induce programmed cell death (apoptosis) by fully suppressing Akt activation.<a onclick="showRef(event, 'ref1 ref4 ref7'); return false;" href="javascript:void(0);" class="ref ref1 ref4 ref7">(1, 4, 7)</a> Therefore, our goal was to identify potent small molecule dual PI3K/mTOR inhibitors, which we hypothesized would exert antitumor activity in a broad array of preclinical models. This hypothesis was validated by the Novartis dual PI3K/mTOR inhibitor <b>1</b> (NVP-BEZ-235, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Compound <b>1</b> is the most advanced PI3K/mTOR inhibitor reported and is currently undergoing phase II clinical trials.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In this publication, we describe the discovery of triazolopyrimidines and their lead optimization, culminating in the novel dual PI3K/mTOR inhibitor <b>3</b> (PKI-402).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Compound <b>3</b> displayed potent inhibition in all class I PI3Ks (e.g., IC<sub>50</sub> vs PI3Kα = 1 nM) and mTOR. Compound <b>3</b> inhibited growth of a diverse set of human tumor lines in vitro, and it proved to be efficacious in three human tumor xenograft models.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of known PI3K inhibitors (<b>1</b> and <b>2</b>) and of novel compound <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The versatility of fused 4-morpholino-2-arylpyrimidines as PI3K/mTOR inhibitors has been demonstrated impressively by the discovery of <b>2</b> (GDC-0941), a PI3Kα isoform selective inhibitor built on a thieno[3,2,<i>d</i>]pyrimidine core,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and by the introduction of pyridofuranopyrimidines,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> imidazolopyrimidines,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> pyrrolopyrimidines<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> as dual PI3K/mTOR inhibitors or pyrazolopyrimidines<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> that function as highly selective mTOR inhibitors. However, despite the fact that highly selective PI3Kα<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and mTOR<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> inhibitors have been introduced recently, only one preclinically validated dual PI3K/mTOR inhibitor, utilizing a fused pyrimidine scaffold bearing a morpholine, has been disclosed to date.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Herein, we report the discovery of the novel triazolopyrimidine scaffold and our lead optimization in this series, resulting in the discovery of <b>3</b>, a highly in vivo efficacious dual PI3K/mTOR inhibitor.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure and biological profile of initial discovery lead <b>4</b> and the triazolopyrimidine lead <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of triazolopyrimidine <b>5</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) is shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Nitrobarbituric acid <b>6</b><a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> was chlorinated using POCl<sub>3</sub> and DMA to give 5-nitrotrichloropyrimidine <b>7</b> in 13% yield.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Pyrimidine <b>7</b> was reacted with morpholine at 0 °C to give the 4-morpholino-5-nitro-2,6-dichloropyrimidine <b>8</b>, which was aminated with 4-amino-1-benzylpiperidine in THF in the presence of NEt<sub>3</sub> to give <b>9</b>. Reduction<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>of <b>9</b> with Raney Ni and N<sub>2</sub>H<sub>4</sub> gave the bis-amino analogue <b>10</b>, which was cyclized<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> using NaNO<sub>2</sub> in AcOH at 0 °C to yield triazolopyrimidine <b>11</b>.</div><div class="NLM_p">For the introduction of C-2 aryl groups, Suzuki reaction of <b>11</b> with 3-hydroxymethylphenyl boronate was used to give <b>5</b> in good yield. This synthetic sequence can be applied to the synthesis of any 3-substituted 5-aryltriazolopyrimidine by varying the primary amine or arylboronic acid or ester.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Triazolopyrimidine <b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) POCl<sub>3</sub>, Me<sub>2</sub>NC<sub>6</sub>H<sub>5</sub>, <i>T</i> < 30 °C, 13%; (b) NEt<sub>3</sub>, morpholine, 0 °C, 92%; (c) 4-amino-1-benzylpiperidine, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 78%; (d) Raney Ni, MeOH, N<sub>2</sub>H<sub>4</sub>, 63%; (e) NaNO<sub>2</sub>, AcOH, 0 °C, 54%; (f) (Ph<sub>3</sub>P)<sub>4</sub>Pd, 3-hydroxymethylphenylboronic acid, Na<sub>2</sub>CO<sub>3</sub>, DME, 140 °C, 1 h microwave, 45%.</p></p></figure><div class="NLM_p">A similar route was used to synthesize <i>N</i>-3-alkyltriazolopyrimidines <b>14</b>−<b>32</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Compound <b>8</b> was reacted with the appropriate primary amines (in this case MeNH<sub>2</sub>, EtNH<sub>2</sub>, <i>i</i>-PrNH<sub>2</sub>, and <i>c</i>-PrNH<sub>2</sub>) and subsequently converted to <b>12a</b>−<b>d</b> as outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> for compound <b>11</b>. Then <b>12a</b>−<b>d</b> were converted to anilines <b>13a</b>−<b>d</b> by reaction with 4-aminophenylboronic acid pinacol ester under Suzuki conditions. Intermediates <b>13a</b>−<b>d</b> were condensed with the appropriate isocyanates to yield urea derivatives <b>14</b>−<b>32</b>. Alternatively, compounds <b>13a</b>−<b>d</b> were reacted with triphosgene and the appropriate aromatic and heteroaromatic amines to form ureido analogues <b>14</b>−<b>30</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i>-3-Alkyl-2-arylureidotriazolopyrimidines <b>14</b>−<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-aminophenylboronic acid pinacol ester, (Ph<sub>3</sub>P)<sub>4</sub>Pd, Na<sub>2</sub>CO<sub>3</sub>, DME, 140 °C, 1 h, microwave, 57%; (b) triphosgene, R<sub>2</sub>NH<sub>2</sub>, Et<sub>3</sub>N, THF or R<sub>2</sub>NCO, THF.</p></p></figure><div class="NLM_p">The synthesis of substituted amides is shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Compound <b>29</b> was saponified using NaOH in THF to obtain acid <b>31</b>, which was coupled with the appropriately substituted amines via HOBT and EDCI (or alternatively HBTU) activation to yield amides <b>3</b> and <b>32</b>−<b>38</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 4-Benzamidoureido Analogues <b>3</b> and <b>32</b>−<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOH, THF, H<sub>2</sub>O, 85%; (b) HOBT, EDCI (or HBTU), Et<sub>3</sub>N, RR′NH, THF.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47532" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47532" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All final compounds <b>3</b> and <b>14</b>−<b>38</b> were tested in vitro against PI3Kα, PI3Kγ, and mTOR.</div><div class="NLM_p">Our primary assay for inhibition of PI3Kα and PI3Kγ enzymes was a fluorescence polarization format assay.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Our primary optimization was directed at improving potency against PI3Kα. However, we are showing potency against PI3Kγ to illustrate the selectivity of our compounds over class IB isoforms, while the possible role of PI3Kγ in cancer remains unclear.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Our molecular modeling is based on cocrystals of inhibitors with PI3Kγ. Hence, predictions using molecular modeling only make sense when the series has good potency against PI3Kα and PI3Kγ. For mTOR enzyme potency, we used a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) platform enzyme-linked immunosorbent assay (ELISA).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Cell growth inhibition was evaluated in MDA-361 [breast, human epidermal growth factor receptor (Her)2+/PI3KCA mutant] and PC3 (prostate, PTEN mutant) human tumor cell lines.</div><div class="NLM_p">Because of the high degree of homology in the adenosine 5′-triphosphate (ATP) binding pocket and the similarity of their cores, all 4-morpholino-2 arylpyrimidines are expected to bind in the ATP binding pocket of mTOR, p110α, and p110γ in a similar binding mode, with the morpholine oxygen binding to the hinge region Val851 and the substituents at the aryl group in the 2-position interacting with Asp810 and Lys883. X-ray crystallography studies with PI3Kγ, molecular modeling and unpublished SAR results indicated that, in fact, those three interactions are crucial for potency against PI3Kα and mTOR. Therefore, we felt that modifying fused pyrimidines would give us the best chance to successfully develop a dual PI3K/mTOR inhibitor.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biological Data and Physical Properties for Heteroarylureidotriazolopyrimidines <b>14</b>−<b>24</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top"><th align="center"> </th><th class="rowsep1" colspan="5" align="center" char=".">IC<sub>50</sub> [nM]<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th align="center" char="."> </th><th align="center" char="."> </th></tr><tr valign="top"><th align="center">compd</th><th align="center" char=".">PI3Kα</th><th align="center" char=".">PI3Kγ</th><th align="center" char=".">mTOR</th><th align="center" char=".">MDA-361</th><th align="center" char=".">PC3</th><th align="center" char=".">sol.<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> at pH 7.4</th><th align="center" char="."><i>t</i><sub>1/2</sub>(rat) [min]<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>14</b></td><td align="char" char=".">5.0</td><td align="char" char=".">18.5</td><td align="char" char=".">0.63</td><td align="char" char=".">35</td><td align="char" char=".">49</td><td align="char" char=".">18</td><td align="char" char=".">27</td></tr><tr valign="top"><td align="left"><b>15</b></td><td align="char" char=".">5.0</td><td align="char" char=".">21.5</td><td align="char" char=".">0.51</td><td align="char" char=".">54</td><td align="char" char=".">67</td><td align="char" char=".">0</td><td align="char" char=".">>30</td></tr><tr valign="top"><td align="left"><b>16</b></td><td align="char" char=".">6.0</td><td align="char" char=".">13.5</td><td align="char" char=".">0.84</td><td align="char" char=".">31</td><td align="char" char=".">70</td><td align="char" char=".">0</td><td align="char" char=".">21</td></tr><tr valign="top"><td align="left"><b>17</b></td><td align="char" char=".">9.5</td><td align="char" char=".">25.0</td><td align="char" char=".">0.89</td><td align="char" char=".">74</td><td align="char" char=".">96</td><td align="char" char=".">0</td><td align="char" char=".">19</td></tr><tr valign="top"><td align="left"><b>18</b></td><td align="char" char=".">10.5</td><td align="char" char=".">48.5</td><td align="char" char=".">0.57</td><td align="char" char=".">39</td><td align="char" char=".">91</td><td align="char" char=".">1</td><td align="char" char=".">24</td></tr><tr valign="top"><td align="left"><b>19</b></td><td align="char" char=".">10.5</td><td align="char" char=".">49.0</td><td align="char" char=".">2.95</td><td align="char" char=".">198</td><td align="char" char=".">281</td><td align="char" char=".">1</td><td align="char" char=".">12</td></tr><tr valign="top"><td align="left"><b>20</b></td><td align="char" char=".">10.5</td><td align="char" char=".">48.5</td><td align="char" char=".">0.57</td><td align="char" char=".">67</td><td align="char" char=".">90</td><td align="char" char=".">1</td><td align="char" char=".">24</td></tr><tr valign="top"><td align="left"><b>21</b></td><td align="char" char=".">6.5</td><td align="char" char=".">22.0</td><td align="char" char=".">3.70</td><td align="char" char=".">184</td><td align="char" char=".">366</td><td align="char" char=".">2</td><td align="char" char=".">9</td></tr><tr valign="top"><td align="left"><b>22</b></td><td align="char" char=".">2.5</td><td align="char" char=".">11.5</td><td align="char" char=".">3.00</td><td align="char" char=".">81</td><td align="char" char=".">133</td><td align="char" char=".">1</td><td align="char" char=".">10</td></tr><tr valign="top"><td align="left"><b>23</b></td><td align="char" char=".">3.0</td><td align="char" char=".">19.5</td><td align="char" char=".">3.05</td><td align="char" char=".">73</td><td align="char" char=".">149</td><td align="char" char=".">0</td><td align="char" char=".">15</td></tr><tr valign="top"><td align="left"><b>24</b></td><td align="char" char=".">8.0</td><td align="char" char=".">37.0</td><td align="char" char=".">21.00</td><td align="char" char=".">196</td><td align="char" char=".">252</td><td align="char" char=".">3</td><td align="char" char=".">11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">The values are an average of at least two separate determinations with a typical variation of less than ±30%.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">In μg/mL.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Half-life of drug when incubating with rat liver microsomes.</p></div></div></div><div class="NLM_p">Imidazolopyrimidine <b>4</b> was identified as a potent and selective PI3Kα inhibitor. Replacing the “CH” of the imdazole ring <b>4</b> with a “N” led to triazolopyrimidine <b>5</b>, which exhibited a lower cLogP value and slightly higher topological polar surface area (TPSA) than <b>4</b>. In addition, <b>5</b> showed similar potency against PI3Kα but better potency against PC3 and MDA-361 cells relative to compound <b>4</b>. However, compound <b>5</b> showed limited solubility and poor microsomal stability caused by the OH group as a metabolic hot spot. A plethora of OH bioisosteres have already been published for fused pyrimidines.<a onclick="showRef(event, 'ref6 ref10 ref16'); return false;" href="javascript:void(0);" class="ref ref6 ref10 ref16">(6, 10, 16)</a> Recently, it has been shown by Zask et al.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> that incorporation of a urea appendage in the pyrazolopyrimidine core not only improved the potency against PI3Kα and mTOR but also increased metabolic stability. Hence, we explored this ureido appendage with triazolopyrimidines carrying small alkyl substitutents at the N-3 position to obtain potent PI3K/mTOR inhibitors with low molecular weight and good microsomal stability.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biological Data and Physical Properties for 4-Arylureidotriazolopyrimidines <b>25</b>−<b>30</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top"><th align="center"> </th><th class="rowsep1" colspan="5" align="center" char=".">IC<sub>50</sub> [nM]<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th align="center" char="."> </th><th align="center" char="."> </th></tr><tr valign="top"><th align="center">compd</th><th align="center" char=".">PI3Kα</th><th align="center" char=".">PI3Kγ</th><th align="center" char=".">mTOR</th><th align="center" char=".">MDA-361</th><th align="center" char=".">PC3</th><th align="center" char=".">sol.<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> at pH 7.4</th><th align="center" char="."><i>t</i><sub>1/2</sub>(rat) [min]<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>25</b></td><td align="char" char=".">23.5</td><td align="char" char=".">69.0</td><td align="char" char=".">1.60</td><td align="char" char=".">84</td><td align="char" char=".">171</td><td align="char" char=".">0</td><td align="char" char=".">7</td></tr><tr valign="top"><td align="left"><b>26</b></td><td align="char" char=".">3.5</td><td align="char" char=".">24.8</td><td align="char" char=".">0.32</td><td align="char" char="."><30</td><td align="char" char=".">55</td><td align="char" char=".">0</td><td align="char" char=".">21</td></tr><tr valign="top"><td align="left"><b>27</b></td><td align="char" char=".">2.4</td><td align="char" char=".">12.2</td><td align="char" char=".">0.39</td><td align="char" char=".">28</td><td align="char" char=".">65</td><td align="char" char=".">6</td><td align="char" char=".">21</td></tr><tr valign="top"><td align="left"><b>28</b></td><td align="char" char=".">3.6</td><td align="char" char=".">17.5</td><td align="char" char=".">0.31</td><td align="char" char=".">38</td><td align="char" char=".">57</td><td align="char" char=".">0</td><td align="char" char=".">9</td></tr><tr valign="top"><td align="left"><b>29</b></td><td align="char" char=".">23.3</td><td align="char" char=".">84.5</td><td align="char" char=".">2.55</td><td align="char" char=".">199</td><td align="char" char=".">285</td><td align="char" char=".">0</td><td align="char" char=".">15</td></tr><tr valign="top"><td align="left"><b>30</b></td><td align="char" char=".">25.0</td><td align="char" char=".">78.0</td><td align="char" char=".">0.35</td><td align="char" char=".">47</td><td align="char" char=".">110</td><td align="char" char=".">1</td><td align="char" char=".">25</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">The values are an average of at least two separate determinations with a typical variation of less than ±30%.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">In μg/mL.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Half-life of drug when incubating with rat liver microsomes.</p></div></div></div><div class="NLM_p">The biological data for analogues <b>14</b>−<b>24</b> are compiled in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. All heteroaryl derivatives (<b>14</b>−<b>24</b>) with small groups at N-3 showed potent inhibition of PI3Kα enzyme activity and potent inhibition of MDA-361/PC3-cell growth. The 4-pyridyl substituted urea analogues <b>14</b>−<b>16</b> exhibited good activity against PI3Kα, mTOR, PC3, and MDA-361. In terms of potent inhibition of PI3Kα enzyme activity and potent inhibition of MDA-361/PC3 cell growth, compounds are ranked in the order Et = <i>c</i>-Pr > <i>i</i>-Pr. However, the ethyl analogue <b>14</b> showed the best solubility compared to <b>15</b> and <b>16</b>. Compounds <b>14</b>−<b>16</b> also showed acceptable microsomal stability. Almost equally good potency was observed for the 3-pyridyl analogues <b>17</b>−<b>20</b>. The <i>i</i>-Pr analogue <b>18</b> exhibited the best cell potency in this subset, while <i>c</i>-Pr (<b>20</b>) and Et (<b>17</b>) were equipotent in enzyme and cells, and the Me substituted analogue <b>19</b> exhibited decreased potency against PI3Kα and cells. Interestingly, when an additional methyl group was introduced to the 3-pyridine core in <b>24</b>, we observed decreased cell potency compared to <b>17</b>. The 2-thiophene analogues <b>21</b>−<b>23</b> were highly potent against PI3Kα, mTOR, and cells. Here, ethyl analogue <b>22</b> showed the best potency against PI3Kα and against cells, establishing the order Et > <i>c</i>-Pr > Me. However, the thiophene analogues <b>21</b>−<b>23</b> showed only modest microsomal stability and poor solubility at physiological pH. Other heteroaryl analogues such as 3-pyrrole, isoxazole, or 2-thiazole were screened as well, but they showed only moderate potency against PI3Kα and in cells and are not shown here. A number of compounds where R<sub>2</sub> = Ph demonstrated excellent potency against PI3Kα, mTOR, and PC3/MDA-361 cells. Especially, compound <b>26</b> appeared to be a potent inhibitor (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). However, <b>26</b> showed poor solubility and only moderate microsomal stability. Amides <b>27</b> and <b>28</b> showed similar good cell and enzyme potency relative to <b>26</b>. In vitro biomarker studies revealed excellent suppression of Akt T308 phosphorylation (IC<sub>50</sub> = 8 nM) in MDA-361 cells after 4 h of incubation with drug, which confirms correlation of the antiproliferative effect of <b>27</b> via PI3K/Akt pathway inhibition. For this study, MDA-361 cells were incubated with <b>27</b> for 4 h. In lieu of directly monitoring cellular PIP3 levels, compound inhibition of PI3K in MDA-361cells was demonstrated by potent suppression of Akt phosphorylation at T308. Suppression of pAkt-T308 linked the antiproliferative effect of <b>27</b> with PI3K/Akt pathway inhibition. Suppression of pAkt (T308) by <b>27</b> was measured by Western blot, using a phosphorylated Akt specific antibody (Cell Signaling Technology). Phosphoblot IC<sub>50</sub> values were determined by densitometric scans of Western blots.</div><div class="NLM_p">Attaching other solubilizing groups such as Me<sub>2</sub>N (<b>25</b>) or morpholine (<b>30</b>) in the 4-position led to only moderately potent PI3Kα inhibitors with high potency against mTOR.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Modeling studies of analogue <b>27</b> docked in a homology model of PI3Kα, based on PI3Kγ crystal structures.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Among the various 4-substituted phenyl analogues, <b>27</b> and <b>28</b> looked the most interesting because of their high potency in enzyme and cell assays. Molecular modeling of compound <b>27</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) shows the crucial hydrogen bonding interactions of the morpholine oxygen to the hinge region Val851 and of the urea to Asp810 and Lys802. Since the amide moiety is pointing away from the binding pocket toward the solvent, this is a good position to improve solubility and/or metabolic stability, with minimal impact on enzyme and cell potency. Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> shows the biological data for amido analogues <b>3</b> and <b>32</b>−<b>38</b> synthesized to probe this hypothesis.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biological Data and Physical Properties for 4-Benzamido Analogues <b>3</b> and <b>32</b>−<b>38</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th align="center"> </th><th colspan="6" align="center">IC<sub>50</sub> [nM]<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th colspan="2" align="center">sol.<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> at</th><th colspan="3" align="center"><i>t</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr><tr valign="top"><th align="center">compd</th><th align="center">PI3Kα</th><th align="center">PI3Kγ</th><th align="center">mTOR</th><th align="center">MDA-361</th><th align="center">PC3</th><th align="center">Akt T308<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th align="center">pH 3.0</th><th align="center">pH 7.4</th><th align="center">human</th><th align="center">nude mouse</th><th align="center">rat</th></tr></thead><tbody><tr valign="top"><td align="left"><b>3</b></td><td align="left">1.4</td><td align="left">9.2</td><td align="left">1.70</td><td align="left">8</td><td align="left">21</td><td align="left">5</td><td align="left">100</td><td align="left">0</td><td align="left">>30</td><td align="left">>30</td><td align="left">15</td></tr><tr valign="top"><td align="left"><b>32</b></td><td align="left">3.0</td><td align="left">17.2</td><td align="left">0.56</td><td align="left">29</td><td align="left">33</td><td align="left">27</td><td align="left">ND</td><td align="left">1</td><td align="left">>30</td><td align="left">29</td><td align="left">16</td></tr><tr valign="top"><td align="left"><b>33</b></td><td align="left">1.4</td><td align="left">12.3</td><td align="left">0.75</td><td align="left">16</td><td align="left">17</td><td align="left">8</td><td align="left">ND</td><td align="left">1</td><td align="left">>30</td><td align="left">ND</td><td align="left">14</td></tr><tr valign="top"><td align="left"><b>34</b></td><td align="left">6.0</td><td align="left">33.0</td><td align="left">2.70</td><td align="left">68</td><td align="left">96</td><td align="left">47</td><td align="left">ND</td><td align="left">0</td><td align="left">>30</td><td align="left">27</td><td align="left">21</td></tr><tr valign="top"><td align="left"><b>35</b></td><td align="left">1.0</td><td align="left">12.0</td><td align="left">0.50</td><td align="left">13</td><td align="left">52</td><td align="left">16</td><td align="left">>100</td><td align="left">>100</td><td align="left">>30</td><td align="left">28</td><td align="left">29</td></tr><tr valign="top"><td align="left"><b>36</b></td><td align="left">6.8</td><td align="left">22.0</td><td align="left">1.21</td><td align="left">36</td><td align="left">88</td><td align="left">65</td><td align="left">4.0</td><td align="left">1</td><td align="left">16</td><td align="left">19</td><td align="left">23</td></tr><tr valign="top"><td align="left"><b>37</b></td><td align="left">3.2</td><td align="left">25.0</td><td align="left">1.10</td><td align="left">24</td><td align="left">67</td><td align="left">74</td><td align="left">100</td><td align="left">1</td><td align="left">ND</td><td align="left">28</td><td align="left">17</td></tr><tr valign="top"><td align="left"><b>38</b></td><td align="left">2.4</td><td align="left">9.0</td><td align="left">2.20</td><td align="left">41</td><td align="left">116</td><td align="left">44</td><td align="left">100</td><td align="left">100</td><td align="left">30</td><td align="left">26</td><td align="left">26</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">The values are an average of at least two separate determinations with a typical variation of less than ±30%.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">In μg/mL.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Half-life of drug when incubating with liver microsomes of the species shown.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Phosphoblot IC<sub>50</sub> values were determined by densitometric scans of Western blots.</p></div></div></div><div class="NLM_p">As can be seen from the onset, introduction of an amido moiety at the 4-position of the phenyl in the urea appendage improved the enzyme and cell potencies and the microsomal stability. A comparison of the <i>N</i>-alkyamides <b>32</b> and <b>34</b> shows that introduction of alkyl substituents can increase cell potency of the amido analogues. However, this effect depends on the size of the alkyl group, so the <i>n</i>-Bu derivate (<b>34</b>) showed about 2-fold lower cell and enzyme potency relative to <b>32</b>. The tertiary amide <b>33</b> demonstrated increased cell potency over <b>32</b> but exhibited a similar stability profile. Excellent potency in PI3Kα, mTOR, and cells was observed for <i>N</i>,<i>N</i>-dimethylaminoethyleneamide <b>35</b>. This compound showed good aqueous solubility at pH 3 and pH 7 and very good stability in rat, nude mouse, and especially human microsomes. The piperazineamide <b>3</b> exhibited potency comparable to that of <b>35</b> against PI3Kα and mTOR. However, cell potency was further enhanced by 2-fold for <b>3</b>, with an IC<sub>50</sub> value well below 10 nM against MDA-361 cells and an IC<sub>50</sub> value of 21 nM against PC3 cells. Compound <b>3</b> also exhibited good pharmaceutical properties, such as good stability in nude mouse and human microsomes and aqueous solubility at pH 3. Replacing the <i>N</i>,<i>N</i>-dimethylaminoethyleneamide (<b>35</b>) with <i>N</i>,<i>N</i>-dimethylaminopropyleneamide (<b>38</b>) led to decreased (2- to 3-fold) potency in cell proliferation assays. Also, substituting the <i>N</i>,<i>N</i>-dimethylamino group with a 2-pyridyl group (<b>36</b>) or a 4-methylpiperazinyl group (<b>37</b>) led to lower potency against cells (MDA-361, PC3). In addition, <b>36</b> exhibited weaker potency against PI3Kα and mTOR than <b>35</b>, as well as low aqueous solubility and only modest microsomal stability in all species.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo biomarker analysis of <b>35</b> given at 50 mpk (iv) to MDA-361 tumor bearing nude mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vivo biomarker analysis at 8 h after <b>3</b> was administered at 25, 50, and 100 mpk (iv) to MDA-361 tumor bearing nude mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More importantly for amido analogues <b>3</b> and <b>32</b>−<b>38</b> the cell potency translated to the suppression of pAkt-T308, the most relevant PI3Kα specific biomarker. Among compounds <b>3</b> and <b>32</b>−<b>38</b>, the best in vitro biomarker suppression was found for <b>35</b> and <b>3</b>. Therefore, <b>35</b> and <b>3</b> were taken forward for in vivo biomarker studies in MDA-361 xenograft bearing mice. Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> show both compounds <b>35</b> and <b>3</b> given at 50 mpk, iv, suppressed pAkt-T308, pAkt-S473, P70S6K, and pS6 (pAkt-S473, P70S6K, and pS6 are mTOR specific biomarkers). Compound <b>3</b> administered at 50 and 100 mpk, iv, not only suppressed all the PI3K/mTOR biomarkers for at least 8 h (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) but also induced cleaved poly ADP-ribose polymerase (PARP), a marker for cells undergoing apoptosis.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">Pharmacokinetic analysis showed that the plasma concentration of <b>35</b> was 1229 ng/mL and tumor concentration was 2130 ng/mL at 4 h after a single 50 mg/kg iv dose. For compound <b>3</b>, plasma level was 525 ng/mL and tumor level was 2219 ng/mL at 8 h after a single 50 mg/kg iv dose. For both compounds <b>3</b> and <b>35</b> an excellent correlation between drug concentration in the plasma and tumor and biochemical response (biomarker pattern) was observed. However, <b>3</b> showed a better PK profile and longer lasting biomarker suppression in vivo than <b>35</b>, so <b>3</b> was taken forward for in vivo efficacy studies.</div><div class="NLM_p">Evaluation of efficacy was performed in nude mice bearing MDA-361 human breast cancer tumors (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). When 100 mpk of <b>3</b> was given once daily for 5 days (one round), tumor regression was observed with no tumor regrowth until day 70 (not shown). At lower doses (25, 50 mg/kg), initial tumor regression was also observed, but tumor regrowth occurred between day 16 and day 20. Compound <b>3</b> also showed in vivo efficacy against other human tumor xenograft models, including U87 (glioma) and A597 (non-small-cell lung). In these studies, compound <b>3</b> was well tolerated, with no adverse side effects such as weight loss.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor efficacy of <b>3</b> in the MDA-361 (breast, Her2+/PIK3CA mutant) xenograft model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additional analysis of compound <b>3</b> showed that it was Ames negative and selective for class I PI3Ks and mTOR. Selectivity of <b>3</b> was assessed against a panel of 236 human kinases (Invitrogene), where no off-target activity (>50% inhibition) was detected at 10 μM. Compound <b>3</b> is one of several compounds undergoing preclinical evaluation, and we will report further efficacy data in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38103" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38103" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have introduced a novel class of PI3K/mTOR inhibitors, namely, the triazolopyrimidines, which showed better potency than our related imidazolopyrimidines. Studies of various N-3-substitutions established the ethyl group as the best choice. Various aryl- and heteroarylureido appendages were screened resulting in the discovery of 4-benzamido analogues. This set of compounds showed especially high potency against PI3Kα and mTOR enzyme activity and excellent potency in tumor cell proliferation assays. By use of molecular modeling, water solubilizing amino substituents were designed and introduced, leading to the discovery of compounds <b>3</b> and <b>35</b>. These compounds had single digit nanomolar IC<sub>50</sub> values in the PI3Kα and mTOR enzyme assays and in the tumor cell growth inhibition assays. For both compounds <b>3</b> and <b>35</b> cell growth inhibition translated well into both in vitro and in vivo biomarker suppression of pAkt-T308, pAkt-S473, P70S6K, and pS6. Additionally, both compounds <b>3</b> and <b>35</b> induced cleaved PARP (a marker for cells undergoing apoptosis) in vitro. Compound <b>3</b> demonstrated superior in vivo biomarker suppression profile (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) in terms of both duration (8 h) and induction of cleaved PARP. These data suggest that complete and sustained pAkt suppression induced apoptosis in MDA-361 tumor cells in vivo. Subsequently, an in vivo efficacy study with MDA-361 xenograft tumors showed that compound <b>3</b> administered at 100 mg/kg, iv, dx5 (one round) caused both initial tumor regression and no tumor regrowth for 70 days. We are currently evaluating the antitumor efficacy of compound <b>3</b> in other models.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> General Methods</h3><div class="NLM_p">Melting points were determined in open capillary tubes on a Mel-temp melting point apparatus and are uncorrected. <sup>1</sup>H NMR spectra were determined with a Bruker DPX-400 spectrometer at 400 MHz. Chemical shifts are reported in parts per million (δ) relative to residual chloroform (7.26 ppm), TMS (0 ppm), or dimethyl sulfoxide (2.49 ppm) as an internal reference with coupling constants (<i>J</i>) reported in hertz (Hz). The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. Electrospray (ES) mass spectra were recorded in positive or negative mode on a Micromass Platform spectrometer. Electron impact (EI) and high-resolution mass spectra were obtained on a Finnigen MAT-90 spectrometer. Combustion analyses were obtained using Perkin-Elmer series II 2400 CHNS/O analyzer. The purity of compound <b>3</b> was determined by combustion analysis. The purity of compounds <b>18</b>, <b>25</b>, <b>28</b>, <b>30</b>, <b>34</b>, <b>37</b> was determined by analytical LC/MS using an Agilent 1100 LC, equipped with an Agilent MSD mass spectrometer, and by analytical LC using X-Bridge BEH column, MeOH/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% NH<sub>4</sub>OAc), 20 min gradient of 10% MeOH to 90% ACN, monitored by UV absorption at 215 nm. The purity of compounds <b>3</b>, <b>5</b>, <b>13a</b>−<b>d</b>, <b>14</b>−<b>17</b>, <b>19</b>−<b>24</b>, <b>26</b>, <b>27</b>, <b>29</b>, <b>31</b>−<b>33</b>, <b>35</b>, <b>36</b>, and <b>38</b> was determined by analytical LC on a Aquasil C18 column, using MeCN/H<sub>2</sub>O eluent at 0.8 mL/min flow (containing 0.1% formic acid), 5.5 min gradient of 0% MeCN to 100% MeCN, monitoring UV absorption at 254 nm. The purity of all the above-mentioned compounds <b>3</b>, <b>5</b>, <b>13a</b>−<b>d</b>, <b>14</b>−<b>38</b> was found to be >95%. Reverse phase HPLC purifications were performed on a Gilson preparative HPLC system controlled by Unipoint software using a Phenomenex Gemini 100 mm × 30.0 mm. Thin-layer chromatography (TLC) was performed on Merck PLC prescored plates <sub>60</sub>F<sub>254</sub>.The terms “concentrated” and “evaporated” refer to removal of solvents using a rotary evaporator at water aspirator pressure with a bath temperature equal to or less than 40 °C. Unless otherwise noted, reagents were obtained from commercial sources and were used without further purification.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Preparation of 5-Nitro-2,4,6-trichloropyrimidine (<b>7</b>)</h4><div class="NLM_p last">An amount of 19.2 g (111 mmol) of anhydrous 5-nitrobarbituirc acid (<b>6</b>) was suspended in 77 mL (833 mmol, 7.5 equiv) of POCl<sub>3</sub>. To the suspension were added slowly 53 mL (333 mmol, 3 equiv) of <i>N</i>,<i>N</i>-diethylaniline so that the reaction temperature never exceeded 45 °C. A water bath at 28 °C was used to cool the reaction mixture during the addition. (Caution, reaction is strongly exothermic!!!). When addition was completed, the mixture was heated for another 30 min to 45 °C. The reaction mixture was cooled to room temperature and poured onto 600 g of ice−water. The resulting mixture was stirred for 5 min and extracted with Et<sub>2</sub>O (3 × 800 mL). The combined ethereal layers were dried over MgSO<sub>4</sub>. Filtration for removal of MgSO<sub>4</sub> and evaporation of Et<sub>2</sub>O gave a red oil, which was purified by column chromatography on silica gel using 100% CH<sub>2</sub>Cl<sub>2</sub>. The product fractions were unified and the solvent was evaporated to give <b>7</b> as a white solid (3.45 g, 13% yield). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.4, 159.3 ppm. MS (EI) <i>m</i>/<i>z</i> 228.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Preparation 2,6-Dichloro-5-nitro-4-morpholinopyrimidine (<b>8</b>)</h4><div class="NLM_p last">To a solution of 2,4,6-trichloronitropyrimidine <b>7</b> (6.20 g, 27.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (170 mL) at 0 °C was added a solution of morpholine (2.34 g, 27.2 mmol) and NEt<sub>3</sub> (2.74 g, 27.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (70 mL) over a period of 1 h. The reaction mixture was stirred for another 1 h at 0 °C and allowed to warm to 20 °C and stirred for 12 h to drive the reaction to completion. For purification, silica gel (20 g) was added to the reaction mixture and the solvent was removed so that product was adsorbed on the silica gel. The resultant residue was placed on a silica gel column, and the crude material was purified by flash chromatography using CH<sub>2</sub>Cl<sub>2</sub> eluent. After concentration, the product <b>8</b> was obtained as yellow solid (6.90 g, 91% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.62 (m, 4H), 4.17 (m, 4H) ppm. MS (ESI) <i>m</i>/<i>z</i> 279.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Prepration of 5-Chloro-3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine (<b>12b</b>)</h4><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16"> Step 1</h5><div class="NLM_p last">To a cooled solution of ethylamine (2 M solution in THF) (3.94 mL, 7.89 mmol) and NEt<sub>3</sub> (796 mg, 7.89 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at 0 °C was added a solution of 2,6-dichloro-5-nitro-4-morpholinopyrimidine <b>8</b> (2.0 g, 7.2 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) over a period of 0.5 h. The reaction mixture was stirred for another 1 h at 0 °C and allowed to warm to 20 °C and stirred for 1−4 h to drive the reaction to completion. The product was purified by flash chromatography on silica gel by eluting it with CH<sub>2</sub>Cl<sub>2</sub> followed by CH<sub>2</sub>Cl<sub>2</sub>/EA (10:1) to give the product as yellow solid (2.1 g, 100% yield). MS (ESI) <i>m</i>/<i>z</i> 288.</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> Step 2</h5><div class="NLM_p last">In a three-neck flask was suspended under nitrogen atmosphere 2-chloro-<i>N</i><sup>4</sup>-ethyl-6-morpholin-4-ylpyrimidine-4,5-diamine (6 g, 21.87 mmol) and Raney Ni (15 g) in methanol (600 mL). To the stirring reaction mixture was added slowly N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (3 mL, 9 mmol, 9 equiv), and the stirring was continued for 1 h to drive the reduction to completion. The reaction mixture was filtered over Celite and the filtrate was evaporated to obtain the product (<i>N</i><sup>4</sup>-ethyl-2-chloro-6-morpholin-4-ylpyrimidine-4,5-diamine) as light-brown solid (4.1 g, 73% yield). MS (ESI) <i>m</i>/<i>z</i> 258.</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> Step 3</h5><div class="NLM_p last">To a stirred solution of <i>N</i><sup>4</sup>-ethyl-2-chloro-6-morpholin-4-ylpyrimidine-4,5-diamine (4.1 g, 15.89 mmol) in acetic acid/water (1:1) (82 mL) at 0 °C was added aqueous (0.5 N) NaNO<sub>2</sub> solution (41 mL, 20.5 mmol), and the reaction mixture was allowed to stir for 2 h. The off-white solid was collected by filtration and dried in vacum to give the 5-chloro-3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine <b>12b</b> (3.26 g, 76% yield). <sup>1</sup>H NMR (DMSO) δ 1.47 (t, <i>J</i> = 7.3 Hz, 3H), 3.74 (m, 2H), 3.81 (m, 2H), 3.94 (m, 2H), 4.53 (q, 7.3 Hz, 2H), 4.56 (m, 2H) ppm. MS (ESI) <i>m</i>/<i>z</i> 269. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 98.9% purity.</div></div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Preparation of 5-Chloro-3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine (<b>12a</b>)</h4><div class="NLM_p last">5-Chloro-3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine (<b>12a</b>) was synthesized starting from 2,6-dichloro-5-nitro-4-morpholinopyrimidine <b>8</b> (2.75 g, 10 mmol) and methylamine in THF solution (2.5 mL, 10 mmol) as outlined for compound <b>12b</b>. 5-Chloro-3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine <b>12a</b> was obtained as yellow solid (1.3 g, 51% yield). Mp 168 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.87 (m, 4H), 4.07 (m, 2H), 4.17 (s, 3H), 4.68 (m, 2H) ppm. MS (APCI) <i>m</i>/<i>z</i> 255.2.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Preparation of 5-Chloro-3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine (<b>12c</b>)</h4><div class="NLM_p last">5-Chloro-3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine (<b>12c</b>) was synthesized starting from 2,6-dichloro-5-nitro-4-morpholinopyrimidine (2 g, 7.19 mmol) and isopropylamine (424 mg, 7.19 mmol) as outlined for compound <b>12b</b> to obtain 5-chloro-3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine <b>12c</b> as an off-white solid. The product was found to be pure enough for further transformations (1.5 g, 74% yield). <sup>1</sup>H NMR (DMSO) δ 1.58 (d, <i>J</i> = 6.5 Hz, 6H), 3.75 (m, 2H), 3.81 (m, 2H), 3.93 (m, 2H), 4.56 (m, 2H), 5.03 (hep, <i>J</i> = 6.5 Hz, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 283.2. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 99.5% purity.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Preparation of 5-Chloro-3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine (<b>12d</b>)</h4><div class="NLM_p last">Starting from 2,6-dichloro-5-nitro-4-morpholinopyrimidine <b>8</b> (1.38 g, 5 mmol) and cyclopropylamine (54 mg, 6 mmol) and following the procedures as outlined for compound <b>12b</b>, 5-chloro-3-cyclopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine <b>12d</b> was obtained as an off-white solid (940 mg, 61%). MS (ESI) <i>m</i>/<i>z</i> 283.2.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedure for the Preparation of 2-Aryl-7-morpholinotriazolopyrimidines by Suzuki Reaction</h4><div class="NLM_p last">To a microwave processing tube was added dimethoxyethane (1.6 mL), aqueous Na<sub>2</sub>CO<sub>3</sub> (2 M solution) (0.4 mL, 0.8 mmol, 2 equiv), (Ph<sub>3</sub>P)<sub>4</sub>Pd (46 mg, 0.08 mmol), and the appropriately substituted boronic acid or ester (0.75 mmol, 2 equiv) and the 2 chloro-3-alkyl-7-morpholinotriazolopyrimidines (0.38 mmol), and the vessel was sealed. The mixture was heated to 140 °C for 45 min. The solvents were distilled on a rota-evaporator, and the crude compound was purified by silica gel chromatography CH<sub>2</sub>Cl<sub>2</sub>/EA (10:1) to give the product as an off-white solid (76−97% yield).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Preparation of 4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine (<b>13b</b>)</h4><div class="NLM_p last">4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13b</b> was prepared from 5-chloro-3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine <b>12b</b> (1.45 g, 5.40 mmol) and 4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenylamine (1.53 g, 7.03 mmol) following the above general Suzuki procedure to give the titled product <b>13b</b> (1.63 g, 92% yield). <sup>1</sup>H NMR (DMSO) δ 1.52 (t, <i>J</i> = 7.6 Hz, 3H), 3.79 (m, 4H), 4.12 (m, 2H), 4.58 (q, <i>J</i> = 7.6 Hz, 2H), 4.59 (m, 2H), 5.65 (s, 2H), 6.62 (d, <i>J</i> = 8.3 Hz, 2H), 8.15 (d, <i>J</i> = 8.3 Hz, 2H) ppm. MS (ESI) <i>m</i>/<i>z</i> 326. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 99.5% purity.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Preparation of 4-(3-Methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine (<b>13a</b>)</h4><div class="NLM_p last">4-(3-Methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13a</b> was prepared from 5-chloro-3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine <b>12a</b> (1.3 g, 5.1 mmol) and 4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenylamine (2.2 g, 10 mmol) following the general Suzuki procedure to give 4-(3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)aniline <b>13a</b> as a brown solid (900 mg, 56%yield). Mp 153 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.91 (m, 6H), 4.23 (m, 1H), 4.23 (s, 3H), 4.69 (m, 2H), 6.74 (d, <i>J</i> = 8.8 Hz, 2H), 8.31 (d, <i>J</i> = 8.8 Hz, 2H) ppm. MS (ESI) <i>m</i>/<i>z</i> 312.3. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 97.3% purity.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Preparation of 4-(3-Isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine (<b>13c</b>)</h4><div class="NLM_p last">4-(3-Isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13c</b> was prepared from 5-chloro-3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine <b>12c</b> (1.50 g, 5.3 mmol) and 4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenylamine (1.74 g, 7.97 mmol) following the general Suzuki procedure to give the titled product (1.22 g, 74% yield). <sup>1</sup>H NMR (DMSO) δ 1.64 (d, <i>J</i> = 6.8 Hz, 6H), 3.80 (m, 4H), 4.11 (m, 2H), 4.55 (m, 4H), 5.14 (hep, <i>J</i> = 6.8 Hz, 1H), 6.72 (d, <i>J</i> = 9.5 Hz, 2H), 8.19 (d, <i>J</i> = 9.5 Hz, 2H) ppm. MS (ESI) <i>m</i>/<i>z</i> 340. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 95.3% purity.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Preparation of (3-Cyclopropyl-7-morpholino-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)aniline (<b>13d</b>)</h4><div class="NLM_p last">4-(3-Cyclopropyl-7-morpholino-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)aniline <b>13d</b> was prepared from 4-(5-chloro-3-cyclopropyl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-7-yl)morpholine <b>12d</b> (600 mg., 2.14 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline following the general Suzuki procedure to give the product as an off-white solid (700 mg, 97% yield). <sup>1</sup>H NMR (DMSO) δ 1.24 (m, 2H), 1.35 (m, 2H),3.52 (m, 2H), 3.79 (m, 4H), 3.99 (hep, <i>J</i> = 3.8 Hz, 1H) 4.12 (m, 2H), 4.52 (m, 2H), 6.66 (d, <i>J</i> = 9.0 Hz, 2H), 8.17 (d, <i>J</i> = 9.0 Hz, 2H) ppm. MS (ESI) <i>m</i>/<i>z</i> = 338.3. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 96.6% purity.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Preparation of Methyl 4-({[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoate (<b>29</b>)</h4><div class="NLM_p last">To a stirred solution of 4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13b</b> (2.6 g, 8.0 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (65 mL) was added methyl 4-isocyanatobenzoate (1.55 g, 8.8 mmol) in one portion. The mixture was stirred for 8 h, hexane (50 mL) was added, and the solid was collected by filtration. The filter cake was washed with hexane (10 mL) and dried in a vacuum oven to give the product <b>29</b> as an off-white solid (3.06 g, 76% yield). <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.3 Hz, 3H), 3.83 (s, 7H), 4.16 (m, 2H), 4.61 (m, 2H), 4.63 (q, <i>J</i> = 7.3 Hz, 2H), 7.61 (m, 4H), 7.91 (d, <i>J</i> = 9.3 Hz, 2H), 8.39 (d, <i>J</i> = 8.6 Hz, 2H), 9.13 (s, 1H), 9.18 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 503.3. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 95.7% purity.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Preparation of 4-({[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoic Acid (<b>31</b>)</h4><div class="NLM_p last">In a one-neck flask equipped with reflux condenser were suspended methyl 4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoate <b>29</b> (3.54 g, 7.1 mmol) in THF (20 mL), methanol (5 mL), and NaOH (5N)(5 mL, 25 mmol). The mixture was refluxed for 2 h and cooled to 0 °C and acidified (pH < 1) with HCl (6 N). During the acidification a white solid was formed, which was collected by filtration. The filter cake was washed with water (10 mL) and dried in a vacuum oven to give the product <b>31</b> as an off-white solid (3.34 g, 98% yield). <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.3 Hz, 3H), 3.83 (m, 4H), 4.16 (m, 2H), 4.62 (m, 2H), 4.63 (q, <i>J</i> = 7.3 Hz, 2H), 7.60 (m, 4H), 7.88 (d, <i>J</i> = 8.3 Hz, 2H), 8.39 (d, <i>J</i> = 8.8 Hz, 2H), 9.24 (s, 1H), 9.27 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 489.3. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 97.3% purity.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Preparation of 1-[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}urea (<b>3</b>)</h4><div class="NLM_p last">4-({[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoic acid <b>31</b> (1.26 g, 2.57 mmol), 1-methylpiperazine (335 mg, 3.35 mmol), NEt<sub>3</sub> (464 μL, 3.35 mmol), and HOBT (452 mg, 3.35 mmol) were suspended in anhydrous THF (8 mL), and EDCI (640 mg, 3.35 mmol) was added. The mixture was stirred for a minimum of 6 h. The solvent was removed on a rota-evaporator, and the crude mixture was dissolved in DMSO (15 mL) and purified by semipreparative HPLC using (ACN/water/NH<sub>3</sub>) to give after combining product fractions and solvent removal (1.15 g, 79% yield) 1-[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}urea <b>3</b> as a white solid. <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.3 Hz, 3H), 2.20 (s, 3H), 2.33 (m, 4H), 3.50 (m, 4H), 3.83 (m, 4H), 4.15 (m, 2H), 4.62 (m, 2H), 4.63 (q, <i>J</i> = 7.3 Hz, 2H), 7.35 (d, <i>J</i> = 8.6 Hz, 2H), 7.54 (d, <i>J</i> = 8.6 Hz, 2H), 7.61 (d, <i>J</i> = 8.8 Hz, 2H), 8.39 (d, <i>J</i> = 8.8 Hz, 2H), 8.97 (s, 1H), 9.07 (s, 1H) ppm. Anal. Calcd for C<sub>29</sub>H<sub>34</sub>FN<sub>10</sub>O<sub>3</sub> (%): C, 61.04; H, 6.01; N, 24.54. Found: C, 60.85; H, 6.40; N, 24.25. MS (ESI) <i>m</i>/<i>z</i> 571.3. HRMS: calcd 571.288 82, found 571.287 38. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, UV absorption at 215 nm, showed 99.3% purity.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Preparation of (1-Benzylpiperidin-4-yl)-(2-chloro-6-morpholin-4-yl-5-nitropyrimidin-4-yl)amine (<b>9</b>)</h4><div class="NLM_p last">To a cooled solution of 4-amino-1-benzylpiperidine (1.25 g, 6.58 mmol) and NEt<sub>3</sub> (796 mg, 7.89 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at 0 °C was added, over a period of 0.5 h, a solution of 2,6-dichloro-5-nitro-4-morpholinopyrimidine <b>8</b> (1.5 g, 6.58 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The reaction mixture was stirred for another 1 h at 0 °C and allowed to warm to 20 °C and stirred for 4 h to drive the reaction to completion. The product was purified by silica gel column chromatography by eluting it with CH<sub>2</sub>Cl<sub>2</sub> followed by CH<sub>2</sub>Cl<sub>2</sub>/EA (10:1) to give the product <b>9</b> as a yellow solid (2.0 g, 70% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.62 (m, 2H), 2.01 (m, 2H), 2.24 (t, <i>J</i> = 10.8 Hz, 2H), 2.81 (m, 2H), 3.54 (m, 6H), 3.77 (m, 4H), 4.18 (m, 1H), 7.33 (m, 5H), 8.44 (d, <i>J</i> = 7.8 Hz, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 433.1.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Preparation of <i>N</i><sup>4</sup>-(1-Benzylpiperidin-4-yl)-2-chloro-6-morpholin-4-ylpyrimidine-4,5-diamine (<b>10</b>)</h4><div class="NLM_p last">In a three-neck flask was suspended under nitrogen atmosphere (1-benzylpiperidin-4-yl)-(2-chloro-6-morpholin-4-yl-5-nitropyrimidin-4-yl)amine (1.0 g, 2.3 mmol) and Raney Ni (1 g) in methanol (100 mL). To the stirring reaction mixture was added slowly N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (1.2 mL, 21 mmol, 9 equiv), and the stirring was continued for 1 h to drive the reduction to completion. The reaction mixture was filtered over Celite and the filtrate was evaporated to obtain the product <b>10</b> as light-brown solid (900 mg, 97% yield). <sup>1</sup>H NMR (DMSO) δ 1.50 (m, 2H), 1.87 (m, 2H), 2.05 (m, 2H), 2.82 (m, 2H), 2.96 (m, 4H), 3.48 (m, 2H), 3.71 (m, 4H), 4.31 (m, 2H), 6.45 (m, 1H), 7.32 (m, 2H) ppm. MS (ESI) <i>m</i>/<i>z</i> 403.1.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Preparation of 3-(1-Benzylpiperidin-4-yl)-5-chloro-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine (<b>11</b>)</h4><div class="NLM_p last">To a stirred solution of <i>N</i><sup>4</sup>-(1-benzylpiperidin-4-yl)-2-chloro-6-morpholin-4-ylpyrimidine-4,5-diamine <b>10</b> (500 mg, 1.24 mmol) in acetic acid/water (1:1) (5 mL) at 0 °C was added aqueous (0.5 N) NaNO<sub>2</sub> solution (5 mL, 2.5 mmol), and the reaction mixture was allowed to stir for 2 h. The off-white solid was collected by filtration and dried in vacuum to give <b>11</b> (510 mg, 100% yield). MS (ESI) <i>m</i>/<i>z</i> 414.2</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Preparation of {3-[3-(1-Benzylpiperidin-4-yl)-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl]phenyl}methanol (<b>5</b>)</h4><div class="NLM_p last">{3-[3-(1-Benzylpiperidin-4-yl)-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl]phenyl}methanol <b>5</b> was prepared from 3-(1-benzylpiperidin-4-yl)-5-chloro-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine (145 mg, 0.35 mmol) and 3-hydroxymethylphenylboronic acid (106 mg, 0.7 mmol) following the above general procedure for Suzuki reactions. The crude product was dissolved in DMSO (2 mL), filtered, and purified by semipreparative HPLC using ACN/water/NH<sub>3</sub> as mobile phase. After unification of the product fraction and solvent removal, the product was obtained as a white solid (80 mg, 47% yield). <sup>1</sup>H NMR (DMSO) δ 2.10 (m, 2H), 2.31 (m, 4H), 2.99 (m, 2H), 3.58 (s, 2H), 3.82 (m, 4H), 4.16 (m, 2H), 4.60 (m, 2H), 4.60 (d, <i>J</i> = 5.8 Hz, 2H), 4.86 (m, 1H), 5.32 (t, <i>J</i> = 5.8 Hz, 1H), 7.27 (m, 1H), 7.34−7.40 (m, 4H), 7.47 (d, <i>J</i> = 5.1 Hz, 2H), 8.32 (td, <i>J</i> = 5.8, 2.1 Hz, 1H), 8.39 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 486.4. HRMS: calcd 486.261 75, found 486.2607. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 97.7% purity.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Preparation of 1-[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-4-ylurea (<b>14</b>)</h4><div class="NLM_p last">To a stirred solution of triphosgene (68 mg, 0.23 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added 4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13b</b> (100 mg, 0.46 mmol) at 0 °C. The reaction mixture was stirred for 15 min, and 4-aminopyridine (40 mg, 0.46 mmol) and NEt<sub>3</sub> (64 μL, 0.46 mmol) were added. The reaction mixture was stirred for additional 1 h. The solvents were distilled on a rota-evaporator and the crude mixture was purified by semipreparative HPLC (NH<sub>3</sub>-method) to give 1-[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-4-ylurea <b>14</b> (22 mg, 11% yield). <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.3 Hz, 3H), 3.83 (m, 4H), 4.16 (m, 2H), 4.62 (m, 2H), 4.64 (q, 7.3 Hz, 2H), 7.48 (d, <i>J</i> = 5.8 Hz, 2H), 7.61 (d, <i>J</i> = 7.8 Hz, 2H), 7.37−7.42 (m, 4H), 9.23 (s, 1H), 9.27 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 446. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 99.2% purity.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Preparation of 1-[4-(3-Isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-4-ylurea (<b>15</b>)</h4><div class="NLM_p last">To a stirred solution of triphosgene (39 mg, 0.13 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added 4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13c</b> (50 mg, 0.14 mmol) at 25 °C. The reaction mixture was stirred for 15 min, 4-aminopyridine (42 mg, 0.44 mmol) and NEt<sub>3</sub> (62 μL, 0.44 mmol) were added, and the reaction mixture was stirred for an additional 1 h. The solvents were removed in a nitrogen stream and the crude mixture was purified by semipreparative HPLC (TFA method) to give 1-[4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-4-ylurea <b>15</b> (22 mg, 57% yield). MS (ESI) <i>m</i>/<i>z</i> 460. HRMS: calcd 460.220 40, found 460.219 84. Analytical LC/MS, using Aquasil C18 column, ACN/H<sub>2</sub>O eluent at 0.8 mL/min flow (containing 0.1% formic acid), 5.5 min gradient 0% ACN to 100% ACN, monitored by UV absorption at 254 nm, showed 99.5% purity. Analytical LC, using X-Bridge BEH column, MeOH/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% NH<sub>4</sub>OAc), 20 min gradient 10% MeOH to 90% ACN, monitored by UV absorption at 215 nm, showed 99.4% purity.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Preparation of 1-(4-(3-Cyclopropyl-7-morpholino-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl)-3-(pyridin-4-yl)urea (<b>16</b>)</h4><div class="NLM_p last">To a solution of triphosgene (66 mg, 0.223 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added 4-(3-cyclopropyl-7-morpholino-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)aniline <b>13d</b> (150 mg, 0.445 mmol), and the mixture was stirred for 30 min. Then pyridin-4-amine (126 mg, 1.34 mmol) and Et<sub>3</sub>N (187 uL, 1.34 mmol) in CH<sub>2</sub>Cl<sub>2</sub>(1.5 mL) were added and the mixture was stirred overnight. The solvents were removed in a nitrogen stream, and the residue was purified by semipreparative HPLC (TFA method) to give the product <b>16</b> as a white solid (TFA salt) (120 mg, 47% yield). <sup>1</sup>H NMR (DMSO) δ 1.28(m, 2H), 1.39 (m, 2H), 3.82 (m, 4H), 4.04 (hep, <i>J</i> = 3.8 Hz, 1H), 4.15 (m, 2H), 4.58 (m, 2H), 7.67 (d, <i>J</i> = 9.0 Hz, 2H), 7.92 (d, <i>J</i> = 7.0 Hz, 2H), 8.43 (d, <i>J</i> = 9.0 Hz, 2H), 8.61 (d, <i>J</i> = 7.0 Hz, 2H), 9.64 (s, 1H), 10.66 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> = 458.3. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 96.3% purity.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Preparation of 1-[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-3-ylurea (<b>17</b>)</h4><div class="NLM_p last">To a stirred solution of 4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13b</b> (150 mg, 0.46 mmol) in anhydrous CHCl<sub>3</sub> (2 mL) were added pyridine 3-isocyanate (83 mg, 0.69 mmol) and NEt<sub>3</sub> (97 μL, 0.69 mmol). The mixture was stirred for 18 h and the solvents were removed in vacuo to obtain the crude product, which was purified by semipreparative HPLC (NH<sub>3</sub> method), to give 1-[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-3-ylurea <b>17</b> as an off-white solid (55 mg, 26% yield). <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.6 Hz, 3H), 3.83 (m, 4H), 4.18 (m, 2H), 4.62 (m, 2H), 4.64 (q, <i>J</i> = 7.6 Hz, 2H), 7.33 (dd, <i>J</i> = 8.3, 4.0 Hz, 1H), 7.60 (d, <i>J</i> = 8.8 Hz, 2H), 7.97 (ddd, <i>J</i> = 8.3, 2.5, 1.5 Hz, 1H), 8.21 (dd, <i>J</i> = 4.8, 1.5 Hz, 1H), 8.39 (d, <i>J</i> = 8.8 Hz, 2H), 8.62 (d, <i>J</i> = 2.5 Hz, 1H), 8.93 (s, 1H), 9.13 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 446.4. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 99.1% purity.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Preparation of 1-[4-(3-Isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-3-ylurea (<b>18</b>)</h4><div class="NLM_p last">The compound was prepared as described for compound <b>16</b> using triphosgene (39 mg, 0.13 mmol), 4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine (50 mg, 0.14 mmol), 3-aminopyridine (42 mg, 0.44 mmol), and NEt<sub>3</sub> (62 μL, 0.44 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) to give 1-[4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-3-ylurea <b>18</b> (18 mg, 47% yield). MS (ESI) <i>m</i>/<i>z</i> 460. HRMS: calcd 460.220 40, found 460.219 78. Analytical LC/MS, using Aquasil C18 column, ACN/H<sub>2</sub>O eluent at 0.8 mL/min flow (containing 0.1% formic acid), 5.5 min gradient 0% ACN to 100% ACN, monitored by UV absorption at 254 nm, showed >99.5% purity. Analytical LC, using X-Bridge BEH column, MeOH/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% NH<sub>4</sub>OAc), 20 min gradient 10% MeOH to 90% ACN, monitored by UV absorption at 215 nm, showed 96.4% purity.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Preparation of 1-[4-(3-Methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-3-ylurea (<b>19</b>)</h4><div class="NLM_p last">4-(3-Methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)aniline <b>13a</b> (60 mg, 0.19 mmol) and 3-pyridylisocyanate (25 mg, 0.20 mmol) were suspended in THF (2 mL) to obtain 1-[4-(3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-3-ylurea as a solid. The solid was suspended in diethylether and filtered. It was found to be pure enough (60 mg, 72% yield). Mp 272 °C. <sup>1</sup>H NMR (DMSO) δ 3.82 (m, 4H), 4.18 (m, 2H), 4.20 (s, 3H), 4.58 (m, 2H), 7.33 (dd, <i>J</i> = 8.8, 4.8 Hz, 1H), 7.61 (d, <i>J</i> = 8.8 Hz, 2H), 7.97 (m, 1H), 8.21 (m, 1H), 8.40 (d, <i>J</i> = 8.8 Hz, 2H), 8.62 (s, 1H), 8.92 (s, 1H), 9.13 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 432.46. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 97.8% purity.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Preparation of 1-(4-(3-Cyclopropyl-7-morpholino-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl)-3-(pyridin-3-yl)urea (<b>20</b>)</h4><div class="NLM_p last">To a solution of 4-(3-cyclopropyl-7-morpholino-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)aniline <b>13d</b> (120 mg, 0.35 mmol) in CHCl<sub>3</sub> (2 mL) were added Et<sub>3</sub>N (93 μL, 0.668 mmol) and 3-isocyanatopyridine (80 mg, 0.668 mmol). The mixture was stirred overnight and the solvent was evaporated and purified by HPLC (TFA method) to give the product <b>20</b> as a white solid (TFA salt) (112 mg, 55% yield). <sup>1</sup>H NMR (DMSO) δ 1.27 (m, 2H), 1.38 (m, 2H), 3.82 (m, 4H), 4.04 (hep, <i>J</i> = 3.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 2H), 7.66 (m, 1H), 8.19 (m, 1H), 8.38 (m, 1H), 8.40 (d, <i>J</i> = 8.8 Hz, 2H), 8.89 (m, 1H), 9.42 (s, 1H), 9.43 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> = 458.3. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 95.7% purity.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Preparation of [4-(3-Methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-(2-thienyl)urea (<b>21</b>)</h4><div class="NLM_p last">To a solution of 4-(3-methyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)aniline <b>13a</b> (60 mg, 0.19 mmol) in CHCl<sub>3</sub> (2 mL) was added 2-thienyl isocyanate (20 mg, 0.20 mmol). The mixture was stirred overnight. The solvent was evaporated in a N<sub>2</sub> stream and the crude mixture was purified by semipreparative HPLC (NH<sub>3</sub> method) to give the product <b>21</b> as a white solid (62 mg, 72% yield). Mp 182 °C. <sup>1</sup>H NMR (DMSO) δ 3.83 (m, 4H), 4.16 (m, 2H), 4.19 (s, 3H), 4.59 (m, 2H), 6.56 (dd, <i>J</i> = 3.5, 1.5 Hz, 1H), 6.82 (dd, <i>J</i> = 5.5, 3.5 Hz, 1H), 6.89 (dd, <i>J</i> = 5.5, 1.5 Hz, 1H), 7.59 (d, <i>J</i> = 8.8 Hz, 2H), 8.39 (d, <i>J</i> = 8.8 Hz, 2H), 9.35 (s, 1H), 9.99 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> = 437.5. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 96.1% purity.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Preparation of 1-[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-(2-thienyl)urea (<b>22</b>)</h4><div class="NLM_p last">To a stirred solution of 4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13b</b> (150 mg, 0.46 mmol) in anhydrous CHCl<sub>3</sub> (2 mL) was added thienyl 2-isocyanate (87 mg, 0.69 mmol) and NEt<sub>3</sub> (97 μL, 0.69 mmol). The mixture was stirred for 18 h and the solvent was evaporated in a N<sub>2</sub> stream to obtain the crude product, which was purified by semipreparative HPLC (NH<sub>3</sub> method), to give 1-[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-(2-thienyl)urea <b>22</b> as an off-white solid (90 mg, 43% yield). <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.3 Hz, 3H), 3.83 (m, 4H), 4.16 (m, 2H), 4.62 (m, 2H), 4.63 (q, <i>J</i> = 7.3 Hz, 2H), 6.56 (dd, <i>J</i> = 3.5, 1.5 Hz, 1H), 6.83 (dd, <i>J</i> = 5.5, 3.5 Hz, 1H), 6.89 (dd, <i>J</i> = 5.5, 1.5 Hz, 1H), 7.59 (d, <i>J</i> = 8.8 Hz, 2H), 8.38 (d, <i>J</i> = 8.8 Hz, 2H), 9.03 (s, 1H), 9.67 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 451.4. HRMS: calcd 451.165 92, found 451.165 62. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 97.8% purity.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Preparation of 1-(4-(3-Cyclopropyl-7-morpholino-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl)-3-(thiophen-2-yl)urea (<b>23</b>)</h4><div class="NLM_p last">To a solution of 4-(3-cyclopropyl-7-morpholino-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)aniline <b>13d</b> (75 mg, 0.222 mmol) in CHCl<sub>3</sub> (1 mL) was added Et<sub>3</sub>N (46 uL, 0.0.333 mmol) and 2-isocyanatothiophene (42 mg, 0.333 mmol). The mixture was stirred overnight, and the solvent was evaporated in a N<sub>2</sub> stream. The crude material was purified by HPLC (NH<sub>3</sub> method) to give the product as a white solid (51 mg, 50% yield). <sup>1</sup>H NMR (DMSO) δ 1.27 (m, 2H), 1.38 (m, 2H), 3.82 (m, 4H), 4.04 (hep, <i>J</i> = 3.8 Hz, 1H), 4.15 (m, 2H), 4.57 (m, 2H), 6.56 (dd, <i>J</i> = 3.5, 1.5 Hz, 1H), 6.83 (dd, <i>J</i> = 5.5, 3.5 Hz, 1H), 6.90 (dd, <i>J</i> = 5.5, 1.5 Hz, 1H), 7.60 (d, <i>J</i> = 8.8 Hz, 2H), 8.38 (d, <i>J</i> = 8.8 Hz, 2H), 9.05 (s, 1H), 9.69 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> = 463.3. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 95.7% purity.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Preparation of 1-[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-(2-methylpyridin-4-yl)urea (<b>24</b>)</h4><div class="NLM_p last">The compound was prepared as described for <b>16</b> using triphosgene (74 mg, 0.25 mmol), 4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13b</b> (100 mg, 0.31 mmol), 4-amino-2-methylpyridine (100 mg, 0.93 mmol), and NEt<sub>3</sub> (430 μL, 0.44 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) to give 1-[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-(2-methylpyridin-4-yl)urea <b>24</b> (13 mg, 9% yield). <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.6 Hz, 3H), 2.63 (s, 3H) 3.83 (m, 4H), 4.16 (m, 2H), 4.62 (m, 2H), 4.64 (q, <i>J</i> = 7.6 Hz, 2H), 7.66 (d, <i>J</i> = 8.8 Hz, 2H), 7.77 (m, 1H), 7.81 (m, 1H), 8.44 (d, <i>J</i> = 8.8 Hz, 2H), 8.50 (d, <i>J</i> = 6.5 Hz, 1H), 9.88 (s, 1H), 10.53 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 460. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 95.0% purity.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Preparation of 1-(4-Dimethylaminophenyl)-3-[4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]urea (<b>25</b>)</h4><div class="NLM_p last">The compound was prepared as described for compound <b>16</b> using triphosgene (39 mg, 0.13 mmol), 4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13c</b> (50 mg, 0.14 mmol), 4-<i>N</i>,<i>N</i>-dimethylaniline (60 mg, 0.44 mmol), and NEt<sub>3</sub> (62 μL, 0.44 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) to give 1-(4-dimethylaminophenyl)-3-[4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]urea <b>25</b> (26 mg, 63% yield). Analytical LC/MS, using Aquasil C18 column, ACN/ H<sub>2</sub>O eluent at 0.8 mL/min flow (containing 0.1% formic acid), 5.5 min gradient 0% ACN to 100% ACN, monitored by UV absorption at 254 nm, showed 99.5% purity. Analytical LC, using X-Bridge BEH column, MeOH/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% NH<sub>4</sub>OAc), 20 min gradient 10% MeOH to 90% ACN, monitored by UV absorption at 215 nm, showed 96.7% purity. MS (ESI) <i>m</i>/<i>z</i> 502. HRMS: calcd 502.267 35, found 502.265 93.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Preparation of 1-(4-Hydroxymethylphenyl)-3-[4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]urea (<b>26</b>)</h4><div class="NLM_p last">The compound was prepared as described for compound <b>16</b> using triphosgene (39 mg, 0.13 mmol), 4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13c</b> (50 mg, 0.14 mmol), 4-aminobenzyl alcohol (54 mg, 0.44 mmol), and NEt<sub>3</sub> (62 μL, 0.44 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) to give 1-[4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-3-ylurea <b>26</b> (18 mg, 47% yield). <sup>1</sup>H NMR (DMSO) δ 1.66 (d, <i>J</i> = 6.3 Hz, 6H), 3.83 (m, 4H), 4.16 (m, 2H), 4.43 (s, 3H), 4.60 (m, 2H), 5.19 (hep, <i>J</i> = 6.3 Hz, 1H), 7.24 (d, <i>J</i> = 8.8 Hz, 2H), 7.42 (d, <i>J</i> = 8.8 Hz, 2H), 7.59 (d, <i>J</i> = 8.8 Hz, 2H), 8.37 (d, <i>J</i> = 8.8 Hz, 2H), 8.70 (s, 1H), 8.96 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 489. HRMS: calcd 489.235 72, found 489.236 10. Analytical LC/MS, using Aquasil C18 column, ACN/H<sub>2</sub>O eluent at 0.8 mL/min flow (containing 0.1% formic acid), 5.5 min gradient 0% ACN to 100% ACN, monitored by UV absorption at 254 nm, showed 99.5% purity.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Preparation of 1-[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-4-ylurea (<b>27</b>)</h4><div class="NLM_p last">To a stirred solution of triphosgene (39 mg, 0.13 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added 4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13b</b> (50 mg, 0.14 mmol) at 25 °C. The reaction mixture was stirred for 15 min, 4-aminobenzamide (59 mg, 0.44 mmol) and NEt<sub>3</sub> (62 μL, 0.44 mmol) were added, and the reaction mixture was stirred for an additional 1 h. The solvents were removed in a nitrogen stream and the crude mixture was purified by semipreparative HPLC (NH<sub>3</sub> method) to give 1-[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-pyridin-4-ylurea <b>27</b> (22 mg, 57% yield). <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.6 Hz, 3H), 3.83 (m, 4H), 4.16 (m, 2H), 4.62 (m, 2H), 4.64 (q, <i>J</i> = 7.6 Hz, 2H), 7.20 (s, 1H), 7.53 (d, <i>J</i> = 8.8 Hz, 2H), 7.60 (d, <i>J</i> = 8.8 Hz, 2H), 7.83 (d, <i>J</i> = 8.8 Hz, 3H), 8.39 (d, <i>J</i> = 8.8 Hz, 2H), 8.99 (s, 1H), 9.07 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 488. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 96.4% purity.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Preparation of 4-{3-[4-(3-Isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]ureido}benzamide (<b>28</b>)</h4><div class="NLM_p last">The compound was prepared as described for compound <b>16</b> using triphosgene (100 mg, 0.33 mmol), 4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine (140 mg, 0.41 mmol), 4-aminobenzamide (163 mg, 1.2 mmol), and NEt<sub>3</sub> (567 μL, 4.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) to give 4-{3-[4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]ureido}benzamide <b>28</b> (68 mg, 33% yield). <sup>1</sup>H NMR (DMSO) δ 1.66(d, <i>J</i> = 6.3 Hz, 6H), 3.83 (m, 4H), 4.16 (m, 2H), 4.60 (m, 2H), 5.19 (hep, <i>J</i> = 6.3 Hz, 1H), 7.20 (s, 1H), 7.53 (d, <i>J</i> = 8.8 Hz, 2H), 7.60 (d, <i>J</i> = 8.8 Hz, 2H), 7.83 (d, <i>J</i> = 8.8 Hz, 3H), 8.39 (d, <i>J</i> = 8.8 Hz, 2H), 9.00 (s, 1H), 9.08 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 502. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 95.4% purity.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Preparation of 1-[4-(3-Isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-(4-morpholin-4-ylphenyl)urea (<b>30</b>)</h4><div class="NLM_p last">The compound was prepared as described for compound <b>16</b> using triphosgene (39 mg, 0.13 mmol), 4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenylamine <b>13c</b> (50 mg, 0.14 mmol), 4-morpholinylaniline (79 mg, 0.44 mmol), NEt<sub>3</sub> (62 μL, 0.44 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) to give 1-[4-(3-isopropyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]-3-(4-morpholin-4-ylphenyl)urea <b>30</b> (14 mg, 31% yield). Analytical LC/MS, using Aquasil C18 column, ACN/H<sub>2</sub>O eluent at 0.8 mL/min flow (containing 0.1% formic acid), 5.5 min gradient 0% ACN to 100% ACN, monitored by UV absorption at 254 nm, showed 98.5% purity. Analytical LC, using X-Bridge BEH column, MeOH/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% NH<sub>4</sub>OAc), 20 min gradient 10% MeOH to 90% ACN, monitored by UV absorption at 215 nm, showed 97.1% purity. MS (ESI) <i>m</i>/<i>z</i> 544. HRMS: calcd 544.277 92, found 544.277 21.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Preparation <i>N</i>-Ethyl-4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzamide (<b>32</b>)</h4><div class="NLM_p last">A solution of 4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoic acid <b>31</b> (50 mg, 0.102 mmol), Hunig’s base (79 mg, 0.612 mmol), HBTU (116 mg, 0.306 mmol), and NMP (1 mL) was stirred for 1 h at room temperature, and ethylamine (2 M in THF) (77 μL, 0.15 mmol) was added. The stirring was continued overnight. The solvents were removed in a nitrogen stream and the crude mixture was purified by semipreparative HPLC (TFA method) to give the product <b>32</b> as a white solid (16 mg, 30% yield). <sup>1</sup>H NMR (DMSO) δ 1.12 (t, <i>J</i> = 7.3 Hz, 3H), 1.55 (t, <i>J</i> = 7.6 Hz, 3H), 3.28 (m, 1H), 3.83 (m, 4H), 4.16 (m, 2H), 4.62 (m, 2H), 4.64 (q, <i>J</i> = 7.6 Hz, 2H), 7.54 (d, <i>J</i> = 8.8 Hz, 2H), 7.60 (d, <i>J</i> = 8.8 Hz, 2H), 7.80 (d, <i>J</i> = 8.8 Hz, 2H), 8.30 (t, <i>J</i> = 53 Hz, 3H), 8.39 (d, <i>J</i> = 8.8 Hz, 2H), 9.00 (s, 1H), 9.08 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 516.2. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 96.3% purity.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Preparation of 4-({[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)-<i>N</i>,<i>N</i>-dimethylbenzamide (<b>33</b>)</h4><div class="NLM_p last">A solution of 4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoic acid <b>31</b>(50 mg, 0.102 mmol), Hunig’s base (79 mg, 0.612 mmol), HBTU (116 mg, 0.306 mmol), and NMP (1 mL) was stirred for 1 h at room temperature, and HNMe<sub>2</sub> (2 M in THF) (77 μL, 0.15 mmol) was added. The stirring was continued overnight. The solvents were removed in a nitrogen stream and the crude mixture was purified by semipreparative HPLC (TFA method) to give the product <b>33</b> as a white solid (9 mg, 17% yield). <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.6 Hz, 3H), 2.96 (s, 6H), 3.83 (m, 4H), 4.16 (m, 2H), 4.62 (m, 2H), 4.63 (q, <i>J</i> = 7.6 Hz, 2H), 7.37 (d, <i>J</i> = 8.8 Hz, 2H), 7.52 (d, <i>J</i> = 8.8 Hz, 2H), 7.60 (d, <i>J</i> = 8.8 Hz, 2H), 8.39 (d, <i>J</i> = 8.8 Hz, 2H), 8.94 (s, 1H), 9.05 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 516.3. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 99.0% purity.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Preparation of <i>N</i>-Butyl-4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzamide (<b>34</b>)</h4><div class="NLM_p last">A solution of 4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoic acid <b>31</b> (50 mg, 0.102 mmol), Hunig’s base (79 mg, 0.612 mmol), HBTU (116 mg, 0.306 mmol), and NMP (1 mL) was stirred for 1 h at room temperature, and <i>n</i>-butylamine (14 mg, 0.15 mmol) was added. The stirring was continued overnight. The solvents were removed in a nitrogen stream and the crude mixture was purified by semipreparative HPLC (TFA method) to give the product <b>34</b> as a white solid (30 mg, 54% yield). Analytical LC/MS, using Aquasil C18 column, ACN/H<sub>2</sub>O eluent at 0.8 mL/min flow (containing 0.1% formic acid), 5.5 min gradient 0% ACN to 100% ACN, monitored by UV absorption at 254 nm, showed 95.5% purity. Analytical LC, using X-Bridge BEH column, MeOH/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% NH<sub>4</sub>OAc), 20 min gradient 10% MeOH to 90% ACN, monitored by UV absorption at 215 nm, showed 95.5% purity. MS (ESI) <i>m</i>/<i>z</i> 544.3. HRMS: calcd 544.277 92, found 544.278 98.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Preparation of <i>N</i>-[2-(Dimethylamino)ethyl]-4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzamide (<b>35</b>)</h4><div class="NLM_p last">A suspension of 4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoic acid <b>31</b> (200 mg, 0.40 mmol), <i>N</i>,<i>N</i>-dimethylethylendiamine (87 μL, 0.8 mmol), NEt<sub>3</sub> (112 μL, 0.8 mmol), HOBT (110 mg, 0.8 mmol), and EDCI (154 mg, 0.8 mmol) in anhydrous THF (3 mL) gave <i>N</i>-[2-(dimethylamino)ethyl]-4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzamide <b>35</b> as free base. The free base was treated with MeOH/HCl to form the HCl salt of <b>35</b> (89 mg, 37% yield).<sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.6 Hz, 3H), 2.84 (d, <i>J</i> = 5.0 Hz, 6H), 3.26 (dd, <i>J</i> = 11.3 5.0 Hz, 2H), 3.61 (dd, <i>J</i> = 11.3 5.0 Hz, 1H), 3.83 (m, 4H), 4.16 (m, 2H), 4.62 (m, 2H), 4.63 (q, <i>J</i> = 7.6 Hz, 2H), 7.58 (d, <i>J</i> = 8.8 Hz, 2H), 7.61 (d, <i>J</i> = 8.8 Hz, 2H), 7.86 (d, <i>J</i> = 8.8 Hz, 2H), 8.39 (d, <i>J</i> = 8.8 Hz, 2H), 8.63 (t, <i>J</i> = 5 Hz, 1H), 9.48 (m, 2H), 9.68 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 559.3. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 99.0% purity.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Preparation of 4-({[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)-<i>N</i>-(2-pyridin-2-ylethyl)benzamide (<b>36</b>)</h4><div class="NLM_p last">A solution of 4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoic acid <b>31</b> (50 mg, 0.102 mmol), Hunig’s base (79 mg, 0.612 mmol), and HBTU (116 mg, 0.306 mmol) in NMP (1 mL) was stirred for 1 h at room temperature, and 2-(2-aminoethyl)pyridine (19 mg, 0.15 mmol) was added. The stirring was continued overnight. The solvents were removed in a nitrogen stream and the crude mixture was purified by semipreparative HPLC (NH<sub>3</sub> method) to give the product <b>36</b> as a white solid (44 mg, 61% yield). <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.5 Hz, 3H), 3.01(t, <i>J</i> = 6.8 Hz, 2H), 3.61 (q, <i>J</i> = 6.8 Hz, 2H), 3.83 (m, 4H), 4.16 (m, 2H), 4.62 (m, 2H), 4.63 (q, <i>J</i> = 7.5 Hz, 2H), 7.28 (m, 1H), 7.31 (d, <i>J</i> = 8.3 Hz, 1H), 7.54 (d, <i>J</i> = 8.8 Hz, 2H), 7.61 (d, <i>J</i> = 8.8 Hz, 2H), 7.77 (m, 3H), 8.39 (d, <i>J</i> = 8.8 Hz, 2H), 8.46 (t, <i>J</i> = 5.7 Hz, 1H), 8.56 (d, <i>J</i> = 5.0 Hz, 1H), 9.02 (m, 2H), 9.10 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 593.3. HRMS: calcd 593.2732, found 593.2727. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 98.2% purity.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Preparation of 4-({[4-(3-Ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)-<i>N</i>-[2-(4-methylpiperazin-1-yl)ethyl]benzamide (<b>37</b>)</h4><div class="NLM_p last">The compound was prepared as described in the example above using 4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoic acid <b>31</b> (50 mg, 0.1 mmol), 4-methylpiperazinylethanamine (20 mg, 0.2 mmol), NEt<sub>3</sub> (30 μL, 0.2 mmol), HOBT (30 mg, 0.2 mmol), and EDCI (40 mg, 0.2 mmol) in anhydrous THF (1 mL) to give 4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)-<i>N</i>-[2-(4-methylpiperazin-1-yl)ethyl]benzamide <b>38</b> (34 mg, 55% yield). Analytical LC/MS, using Aquasil C18 column, ACN/H<sub>2</sub>O eluent at 0.8 mL/min flow (containing 0.1% formic acid), 5.5 min gradient 0% ACN to 100% ACN, monitored by UV absorption at 254 nm, showed >99.5% purity. Analytical LC, using X-Bridge BEH column, MeOH/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% NH<sub>4</sub>OAc), 20 min gradient 10% MeOH to 90% ACN, monitored by UV absorption at 215 nm, showed 98.4% purity. MS (ESI) <i>m</i>/<i>z</i> 614.3. HRMS: calcd 614.3310, found 614.3303.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Preparation of <i>N</i>-[3-(Dimethylamino)propyl]-4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzamide (<b>38</b>)</h4><div class="NLM_p last">The compound was prepared as described in the example above using 4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoic acid <b>31</b> (100 mg, 0.2 mmol), <i>N</i>,<i>N</i>-dimethylpropyldiamine (40 mg, 0.4 mmol), NEt<sub>3</sub> (56 μL, 0.4 mmol), HOBT (55 mg, 0.4 mmol), and EDCI (77 mg, 0.4 mmol) in anhydrous THF (2 mL) to give <i>N</i>-[3-(dimethylamino)propyl]-4-({[4-(3-ethyl-7-morpholin-4-yl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzamide <b>38</b> as free base. The free base was treated with MeOH/HCl to form the HCl salt of <b>38</b> (39 mg, 32% yield). <sup>1</sup>H NMR (DMSO) δ 1.55 (t, <i>J</i> = 7.3 Hz, 3H), 1.90 (m, 2H), 2.76 (d, <i>J</i> = 4.8 Hz, 6H), 3.08 (m, 2H), 3.32 (6, <i>J</i> = 6.3 Hz, 2H), 3.83 (m, 4H), 4.16 (m, 2H), 4.62 (m, 2H), 4.63 (q, <i>J</i> = 7.3 Hz, 2H), 7.56 (d, <i>J</i> = 8.8 Hz, 2H), 7.61 (d, <i>J</i> = 8.8 Hz, 2H), 7.83 (d, <i>J</i> = 8.8 Hz, 2H), 8.38 (d, <i>J</i> = 8.8 Hz, 2H), 8.54 (t, <i>J</i> = 5.8 Hz, 1H), 9.58 (s, 2H), 9.89 (s, 1H) ppm. MS (ESI) <i>m</i>/<i>z</i> 573.4. Analytical LC, using Prodigy ODS3 column, ACN/H<sub>2</sub>O eluent at 1 mL/min flow (containing 0.05% TFA), 20 min gradient 5% ACN to 95% ACN, monitored by UV absorption at 215 nm, showed 98.4% purity.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Biology Methods</h3><div id="sec6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Enzyme Assays</h4><div class="NLM_p">Enzyme assays were done in fluorescent polarization (FP) format, adapted from the Echelon K-1100 PI3K FP assay kit protocol (1). PIP2 and TAMRA-labeled detector (PIP3-analogue) were purchased from Echelon. Human PI3Kα and PI3Kγ were expressed in SF9 insect cells and purified by GST and/or FLAG affinity columns. Human PI3Kβ, PI3Kδ and the two most common mutant forms of PI3Kα (E545K and H1047R) were purchased from Upstate Biotech. Mouse GRP1 was produced as a GST fusion protein in <i>E. coli</i> and isolated by GST-Sepharose. Assay reaction buffer was 20 mM Hepes, pH 7.5, 2 mM MgCl<sub>2</sub>, 0.05% CHAPS, and 0.01% βME. Assay STOP/detection buffer was 100 mM Hepes, pH 7.5, 4 mM EDTA, 0.05% CHAPS. FP assays were run in Nunc 384-well black polypropylene fluor plates. The FP reaction was run in 20 μL of reaction buffer containing 20 μM PIP2, 25 μM ATP, and >4% DMSO (compound solvent). The reaction was run for 30 min at room temp. The reaction was stopped with 20 μL of STOP/detection buffer containing 10 nM probe and 40 nM GST-GRP. Assay plates were incubated for 2 h, and fluorescence polarization was measured in a Perkin-Elmer Envision plate reader with TAMRA-FP filters.</div><div class="NLM_p last">Selectivity of <b>3</b> was evaluated in a 236 human kinase panel (Invitrogen) at ATP <i>K</i><sub>m</sub> for each enzyme.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Cell Culture and Growth Inhibition Assay</h4><div class="NLM_p">The following cell lines were obtained from ATCC: MDA361, U87MG, A549, and PC3. All cell lines were propagated at 37 °C in 5% CO<sub>2</sub> incubators in growth media recommended by ATCC supplemented with penicillin/streptomycin and 10% fetal calf serum.</div><div class="NLM_p last">Cell growth inhibition was determined using the CellTiter 96 Aqueous nonradioactive cell proliferation assay from Promega. This homogeneous colorimetric method determined the number of viable cells in proliferation assays. The assay was carried out in 96-well format following manufacturer’s instructions, with cell number numbers per well being adjusted on the basis of growth characteristics of the various cell lines used. Assay end point data were quantitated after 72 h of compound exposure using a Victor2 V (Wallac) model 1420 multilabel HTS counter.</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Cell Lysis and Western Blotting</h4><div class="NLM_p last">Cell lysis was done to enable biochemical analysis of PI3K/mTOR signaling pathway proteins after exposure of various cell lines to <b>3</b>. Briefly, 3 × 10<sup>6</sup> cells were seeded onto 6-well microtiter plates (Nunc) 24 h prior to being exposed to these compounds in complete growth medium. Cells were exposed to these compounds for 4 h (unless indicated otherwise in the figures). After exposure to compounds, cell growth medium was removed and cells were washed twice with cold (4 °C) PBS. Cell lysis buffer (0.2 mL) was then added to each microtiter plate well with sufficient mixing to ensure complete cell lysis. Cell lysis buffer consisted of 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na<sub>2</sub>EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, and 1 μg/mL leupeptin. Cell lysates were then spun in a microfuge for 30 s at 14 000 rpm. Supernatant (75 μL) was then combined with 30 μL of 3× protein gel loading buffer [187.5 mM Tris-HCl (pH 6.8), 6% (w/v) SDS, 30% glycerol, 0.03% (w/v) bromophenol blue, and 125 mM DTT]. Samples were boiled for 5 min and then subjected to SDS−PAGE, transferred to nitrocellulose, and probed with various antibodies specific to the protein and phosphoprotein components of the PI3K/Akt/mTOR signaling pathway. Antibodies were obtained from Cell Signaling Technology, and they were anti(α)-Akt, α-phospho(p)-Akt at T308, α-p-Akt at S473, α-4EBP1, α-p-4EBP1 at T37/46, α-p70 S6 kinase, α-p-p70 S6 kinase at T389, α-PARP, α-cleaved PARP at D214, α-p-ENOS at S1177, α-p-GSK3α/β at S21/9, and α-p-PRAS40 at T246. All antibodies were used as recommended by the manufacturer, and specific antigen/antibody interactions were identified by a horseradish peroxidase (HRP) conjugate secondary antibody (Ab) that enabled chemiluminescent detection. <b>3</b> inhibition of protein phosphorylation was quantified from Western blots analyzed on the BioRad Fluor-S MultiImager (Hercules, CA), using Quantity One Analysis software.</div></div><div id="secz" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Establishment of Xenograft Tumors, Efficacy Studies, and Biomarker Analysis</h4><div class="NLM_p">Establishment of tumors, group randomization, tumor, and body weight recording during efficacy studies was described elsewhere.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Briefly, all in vivo studies using nude mice were conducted under an approved Institutional Animal Care and Use Committee protocol. Generally, tumor cells were suspended at 5 × 10<sup>7</sup> cells/mL in cell growth medium and the cell suspension (0.2 mL) was injected subcutaneously (sc) into the flank of a ∼8 week old female nude mice (Charles River, Wilmington, MA). Mice with tumors greater than 100 mm<sup>3</sup> after 1 week were administered vehicle or compound by intravenous (iv) tail vein injection at various dose levels. Injection volumes for <b>3</b> were 0.2 mL in vehicle containing 0.5% methylcellulose and 0.4% polysorbate 80 (Tween-80), with vehicle pH adjusted to 3.5 by lactic acid to fully solubilize <b>3</b>. In tumor bearing mice tumor weight and body weight were monitored two or three times weekly. Tumor weight was calculated by the following formula: tumor weight (mg) = (<i>d</i><sup>2</sup> × <i>d</i>/2), where <i>d</i> and <i>d</i> are the shortest and longest diameters of the tumor, respectively, measured in millimeters. Statistical analysis (Student’s <i>t</i> test) of the log of the relative tumor growth compared treated groups with the control group. Statistically significant reduction in the tumor growth of treated groups compared to controls (vehicle) was defined as <i>p</i> < 0.05.</div><div class="NLM_p last">Pharmacodynamic (biomarker) measurements were done on tumor bearing female nude mice administered <b>3</b> or vehicle by iv injections as above. Tumor tissue and normal tissue samples were collected from euthanized animals, and tissue was homogenized, washed twice with cold (4 °C) PBS, and then treated with cell lysis buffer. Cell lysis buffer was the same as that described above. As with in vitro samples, cell lysates combined with gel loading buffer were boiled for 5 min and then subjected to SDS−PAGE, transferred to nitrocellulose, and probed with various antibodies specific to the protein and phosphoprotein components of the PI3K/Akt/mTOR signaling pathway.</div></div></div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28240" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28240" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christoph M. Dehnhardt</span> - <span class="hlFld-Affiliation affiliation">Discovery Medicinal Chemistry</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4622232e282e272506313f23322e6825292b"><span class="__cf_email__" data-cfemail="3b5f5e5355535a587b4c425e4f5315585456">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aranapakam M. Venkatesan</span> - <span class="hlFld-Affiliation affiliation">Discovery Medicinal Chemistry</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Efren Delos Santos</span> - <span class="hlFld-Affiliation affiliation">Discovery Medicinal Chemistry</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zecheng Chen</span> - <span class="hlFld-Affiliation affiliation">Discovery Medicinal Chemistry</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Osvaldo Santos</span> - <span class="hlFld-Affiliation affiliation">Discovery Medicinal Chemistry</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Semiramis Ayral-Kaloustian</span> - <span class="hlFld-Affiliation affiliation">Discovery Medicinal Chemistry</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natasja Brooijmans</span> - <span class="hlFld-Affiliation affiliation">Computational Chemistry</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Mallon</span> - <span class="hlFld-Affiliation affiliation">Oncology</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Irwin Hollander</span> - <span class="hlFld-Affiliation affiliation">Oncology</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Larry Feldberg</span> - <span class="hlFld-Affiliation affiliation">Oncology</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judy Lucas</span> - <span class="hlFld-Affiliation affiliation">Oncology</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Inder Chaudhary</span> - <span class="hlFld-Affiliation affiliation">Drug Safety and Metabolism</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ker Yu</span> - <span class="hlFld-Affiliation affiliation">Oncology</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jay Gibbons</span> - <span class="hlFld-Affiliation affiliation">Oncology</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Abraham</span> - <span class="hlFld-Affiliation affiliation">Oncology</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tarek S. Mansour</span> - <span class="hlFld-Affiliation affiliation">Discovery Medicinal Chemistry</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm9014982" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank GVK-Bioscience and Dr. Rocco Galante and Thiru Singanallore for the scale-up of 5-nitro-2,4,6-trichloropyrimidine <b>7</b> and Dr. Anja Dilley for the scale-up compound <b>3</b>. Furthermore, we thank the Pearl River Chemical Technologies group for its support.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23505" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23505" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 17 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Targeting PI3K signaling in cancer: opportunities, challenges and limitations</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm9014982&amp;key=10.1038%2Fnrc2664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm9014982&amp;key=19629070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm9014982&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFylsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=550-562&author=J.+A.+Engelman&title=Targeting+PI3K+signaling+in+cancer%3A+opportunities%2C+challenges+and+limitations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K signalling in cancer: opportunities, challenges and limitations</span></div><div class="casAuthors">Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">550-562</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There are ample genetic and lab. studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells.  Inhibitors targeting this pathway are entering the clinic at a rapid pace.  In this Review, the therapeutic potential of drugs targeting PI3K-Akt signaling for the treatment of cancer is discussed.  I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCwdUnGEC20LVg90H21EOLACvtfcHk0lj3oeKu8cAmHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFylsrg%253D&md5=f0d4cc1fabf879e95f8b76e48cc9c1ad</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2664%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DTargeting%2520PI3K%2520signaling%2520in%2520cancer%253A%2520opportunities%252C%2520challenges%2520and%2520limitations%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D550%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Shaw, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">Ras, PI(3)K and mTOR signaling controls tumor cell growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">441</span><span class="NLM_x">, </span> <span class="NLM_fpage">424</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2006&pages=424-430&author=R.+J.+Shawauthor=L.+C.+Cantley&title=Ras%2C+PI%283%29K+and+mTOR+signaling+controls+tumor+cell+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DR.%2BJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DRas%252C%2520PI%25283%2529K%2520and%2520mTOR%2520signaling%2520controls%2520tumor%2520cell%2520growth%26jtitle%3DNature%26date%3D2006%26volume%3D441%26spage%3D424%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Stauffer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Imidazo[4,5-<i>c</i>]quinolines as inhibitors of the PI3K/PKB-pathway</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1027</span><span class="NLM_x">–</span> <span class="NLM_lpage">1030</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1027-1030&author=F.+Staufferauthor=S.+M.+Mairaauthor=P.+Furetauthor=C.+Garcia-Echeverria&title=Imidazo%5B4%2C5-c%5Dquinolines+as+inhibitors+of+the+PI3K%2FPKB-pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DImidazo%255B4%252C5-c%255Dquinolines%2520as%2520inhibitors%2520of%2520the%2520PI3K%252FPKB-pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1027%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brachmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chene, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pover, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schemaker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1851</span><span class="NLM_x">–</span> <span class="NLM_lpage">1863</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm9014982&amp;key=10.1158%2F1535-7163.MCT-08-0017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm9014982&amp;key=18606717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm9014982&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1851-1863&author=S.+M.+Mairaauthor=F.+Staufferauthor=J.+Brueggenauthor=P.+Furetauthor=C.+Schnellauthor=C.+Fritschauthor=S.+Brachmannauthor=P.+Cheneauthor=A.+De+Poverauthor=K.+Schemakerauthor=D.+Fabbroauthor=D.+Gabrielauthor=M.+Simonenauthor=L.+Murphyauthor=P.+Finanauthor=W.+Sellersauthor=C.+Garcia-Echeverria&title=Identification+and+characterization+of+NVP-BEZ235%2C+a+new+orally+available+dual+phosphatidylinositol+3-kinase%2Fmammalian+target+of+rapamycin+inhibitor+with+potent+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span></div><div class="casAuthors">Maira, Sauveur-Michel; Stauffer, Frederic; Brueggen, Josef; Furet, Pascal; Schnell, Christian; Fritsch, Christine; Brachmann, Saskia; Chene, Patrick; De Pover, Alain; Schoemaker, Kevin; Fabbro, Doriano; Gabriel, Daniela; Simonen, Marjo; Murphy, Leon; Finan, Peter; Sellers, William; Garcia-Echeverria, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1851-1863</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells, providing unique opportunities for anticancer therapeutic intervention.  NVP-BEZ235 is an imidazo[4,5-c]quinoline deriv. that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes.  In cellular settings using human tumor cell lines, this mol. is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest.  The cellular activity of NVP-BEZ235 translates well in in vivo models of human cancer.  Thus, the compd. was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies.  Ex vivo pharmacokinetic/pharmacodynamic analyses of tumor tissues showed a time-dependent correlation between compd. concn. and PI3K/Akt pathway inhibition.  Collectively, the preclin. data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties.  NVP-BEZ235 is currently in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyO784qv52vrVg90H21EOLACvtfcHk0liiuQVIMYXbsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D&md5=5b1979e134dd12065198d86dbc11ce15</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0017%26sid%3Dliteratum%253Aachs%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBrachmann%26aufirst%3DS.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DSchemaker%26aufirst%3DK.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGabriel%26aufirst%3DD.%26aulast%3DSimonen%26aufirst%3DM.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DSellers%26aufirst%3DW.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520NVP-BEZ235%252C%2520a%2520new%2520orally%2520available%2520dual%2520phosphatidylinositol%25203-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitor%2520with%2520potent%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1851%26epage%3D1863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Gibbons, J.; Abraham, R.; Dehnhardt, C. M.; Venkatesan, A. M.; Delos Santos, E.; Chen, Z.; Santos, O.; Ayral-Kaloustain, S.; Brooijmans, N.; Mansour, T. S.</span><span> </span><span class="NLM_article-title">PKI-402, a Dual PI3K/mTOR Inhibitor</span>.  <span class="citation_source-book">Molecular Targets and Cancer Therapeutics</span>, Boston, MA, Nov 15−19, 2009; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Abstract B142.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Mallon&author=I.+Hollander&author=L.+Feldberg&author=J.+Lucas&author=J.+Gibbons&author=R.+Abraham&author=C.+M.+Dehnhardt&author=A.+M.+Venkatesan&author=E.+Delos+Santos&author=Z.+Chen&author=O.+Santos&author=S.+Ayral-Kaloustain&author=N.+Brooijmans&author=T.+S.+Mansour&title=Molecular+Targets+and+Cancer+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMallon%26aufirst%3DR.%26atitle%3DPKI-402%252C%2520a%2520Dual%2520PI3K%252FmTOR%2520Inhibitor%26btitle%3DMolecular%2520Targets%2520and%2520Cancer%2520Therapeutics%26pub%3DAACR%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The identification of 2-(1<i>H</i>-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine(GDC 0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+S.+Pangauthor=G.+Patelauthor=H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H+Ultschauthor=M.+Valentiauthor=+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+identification+of+2-%281H-indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine%28GDC+0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%2BS.%26aulast%3DPatel%26aufirst%3DG.%26aulast%3DPergl-Wilson%26aufirst%3DH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520identification%2520of%25202-%25281H-indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2528GDC%25200941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Hayakawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritomo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koizumi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, P.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-<i>d</i>]pyrimidine derivatives as novel PI3 kinase p110α inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2438</span><span class="NLM_x">–</span> <span class="NLM_lpage">2442</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2438-2442&author=M.+Hayakawaauthor=H.+Kaizawaauthor=H.+Moritomoauthor=T.+Koizumiauthor=T.+Ohishiauthor=M.+Yamanoauthor=M.+Okadaauthor=M.+Ohtaauthor=S.+Tsukamotoauthor=F.+I+Raynaudauthor=P.+Workmanauthor=M.+D.+Waterfieldauthor=P.+Parker&title=Synthesis+and+biological+evaluation+of+pyrido%5B3%E2%80%B2%2C2%E2%80%B2%3A4%2C5%5Dfuro%5B3%2C2-d%5Dpyrimidine+derivatives+as+novel+PI3+kinase+p110%CE%B1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHayakawa%26aufirst%3DM.%26aulast%3DKaizawa%26aufirst%3DH.%26aulast%3DMoritomo%26aufirst%3DH.%26aulast%3DKoizumi%26aufirst%3DT.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DYamano%26aufirst%3DM.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DParker%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520pyrido%255B3%25E2%2580%25B2%252C2%25E2%2580%25B2%253A4%252C5%255Dfuro%255B3%252C2-d%255Dpyrimidine%2520derivatives%2520as%2520novel%2520PI3%2520kinase%2520p110%25CE%25B1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2438%26epage%3D2442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Dehnhardt, C. M.; Venkatesan, A. M.; Chen, Z.; Delos Santos, E.; Santos, O.; Bursavich, M.; Brooijmans, B.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Ayral-Kaloustian, S.; Gibbons, J.; Abraham, R.; Mansour, T. S.</span><span> </span><span class="NLM_article-title">Novel Imidazolopyrimidines as Dual PI3-Kinase/mTor Inhibitors</span>.  <span class="citation_source-book">Proceedings of the 100th Annual Meeting of the American Association for Cancer Research</span>, Denver, CO, Apr 18−22, 2009; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Abstract 2017.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=C.+M.+Dehnhardt&author=A.+M.+Venkatesan&author=Z.+Chen&author=E.+Delos+Santos&author=O.+Santos&author=M.+Bursavich&author=B.+Brooijmans&author=R.+Mallon&author=I.+Hollander&author=L.+Feldberg&author=J.+Lucas&author=K.+S.+Yu+Ayral-Kaloustian&author=J.+Gibbons&author=R.+Abraham&author=T.+S.+Mansour&title=Proceedings+of+the+100th+Annual+Meeting+of+the+American+Association+for+Cancer+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26atitle%3DNovel%2520Imidazolopyrimidines%2520as%2520Dual%2520PI3-Kinase%252FmTor%2520Inhibitors%26btitle%3DProceedings%2520of%2520the%2520100th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%26pub%3DAACR%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Chen, Z.; Venkatesan, A. M.; Dehndardt, C. M.; Ayral-Kaloustian, S.; Mansour, T. S.; Brooijmans, N.; Mallon, R.; Hollander, I.; Yu, K.</span><span> </span><span class="NLM_article-title">Discovery of Novel Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives as PI3-Kinase Inhibitors</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 238th National Meeting of the American Chemical Society, Washington, DC, Aug 16−20, 2009; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=Z.+Chen&author=A.+M.+Venkatesan&author=C.+M.+Dehndardt&author=S.+Ayral-Kaloustian&author=T.+S.+Mansour&author=N.+Brooijmans&author=R.+Mallon&author=I.+Hollander&author=K.+Yu&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Novel%2520Pyrrolo%255B3%252C2-d%255Dpyrimidine%2520Derivatives%2520as%2520PI3-Kinase%2520Inhibitors%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malwitz, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svenson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5013</span><span class="NLM_x">–</span> <span class="NLM_lpage">5016</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900851f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5013-5016&author=A.+Zaskauthor=J.+C.+Verheijenauthor=K.+Curranauthor=J.+Kaplanauthor=D.+J.+Richardauthor=P.+Nowakauthor=D.+J.+Malwitzauthor=N.+Brooijmansauthor=J.+Bardauthor=K.+Svensonauthor=J.+Lucasauthor=L.+Toral-Barzaauthor=W.+Zhangauthor=I.+Hollanderauthor=J.+J.+gibbonsauthor=R.+T.+Abrahamauthor=S.+Ayral-Kaloustianauthor=T.+S.+Mansourauthor=K.+Yu&title=ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin%3A+design+and+synthesis+of+highly+potent+and+selective+pyrazolopyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm900851f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900851f%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DSvenson%26aufirst%3DK.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3Dgibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%253A%2520design%2520and%2520synthesis%2520of%2520highly%2520potent%2520and%2520selective%2520pyrazolopyrimidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5013%26epage%3D5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Fan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mostov, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span> </span><span class="NLM_article-title">A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=341-349&author=Q.+Fanauthor=Z.+A.+Knightauthor=D.+D.+Goldenbergauthor=W.+Yuauthor=K.+E.+Mostovauthor=D.+Stokoeauthor=K.+M.+Shokatauthor=W.+A.+Weiss&title=A+dual+PI3+kinase%2FmTOR+inhibitor+reveals+emergent+efficacy+in+glioma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DQ.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DMostov%26aufirst%3DK.%2BE.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DA%2520dual%2520PI3%2520kinase%252FmTOR%2520inhibitor%2520reveals%2520emergent%2520efficacy%2520in%2520glioma%26jtitle%3DCancer%2520Cell%26date%3D2006%26volume%3D9%26spage%3D341%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Gillman, H.; Blatt, H.</span> <span class="citation_source-book">Organic Syntheses</span>; Wiley & Sons: New York,<span class="NLM_x"> </span><span class="NLM_year">1943</span><span class="NLM_x">; </span>Collect. Vol.  <span class="NLM_volume">II</span>, p  <span class="NLM_fpage">440</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1943&pages=440&author=H.+Gillman&author=H.+Blatt&title=Organic+Syntheses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGillman%26aufirst%3DH.%26btitle%3DOrganic%2520Syntheses%26date%3D1943%26volume%3DII%26spage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Robins, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dille, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, B. E.</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1954</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">933</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo01371a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Robins%2C+R.+K.%3B+Dille%2C+K.+L.%3B+Christensen%2C+B.+E.J.+Org.+Chem.+1954%2C+19%2C+930%E2%80%93933"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjo01371a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01371a010%26sid%3Dliteratum%253Aachs%26aulast%3DRobins%26aufirst%3DR.%2BK.%26aulast%3DDille%26aufirst%3DK.%2BL.%26aulast%3DChristensen%26aufirst%3DB.%2BE.%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1954%26volume%3D19%26spage%3D930%26epage%3D933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Fukskovka, K.; Halishek, L.; Krystof, V.; Lenobel, R.; Strnad, M.</span> PCT Int. Patent. Appl. WO2004/018473,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Fukskovka%2C+K.%3B+Halishek%2C+L.%3B+Krystof%2C+V.%3B+Lenobel%2C+R.%3B+Strnad%2C+M.+PCT+Int.+Patent.+Appl.+WO2004%2F018473%2C+2004."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFukskovka%26aufirst%3DK.%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, S. F.</span><span> </span><span class="NLM_article-title">A directly labeled TR-FRET assay for monitoring phosphoinositide-3-kinase activity</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm9014982&amp;key=10.2174%2F138620706777935360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm9014982&amp;key=16925516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm9014982&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVKrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=565-570&author=X.+Yangauthor=P.+Liauthor=L.+Feldbergauthor=S.+C.+Kimauthor=M.+Bowmanauthor=I.+Hollanderauthor=R.+Mallonauthor=S.+F.+Wolf&title=A+directly+labeled+TR-FRET+assay+for+monitoring+phosphoinositide-3-kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A directly labeled TR-FRET assay for monitoring phosphoinositide-3-kinase activity</span></div><div class="casAuthors">Yang, Xiaoke; Li, Puyao; Feldberg, Larry; Kim, Steven C.; Bowman, Michael; Hollander, Irwin; Mallon, Robert; Wolf, Stanley F.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">565-570</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3Ks) comprise a family of kinases that transfer the terminal phosphate of ATP to phosphoinositides at the 3-hydroxyl of the inositol ring to form phosphoinositide (3,4,5)-triphosphate (PIP3).  The PI3Ks have been shown to play key roles in cell growth, motility, morphol., and survival and thus are of interest as targets in anti-inflammatory and anti-oncogenic drug development.  To facilitate identification of novel and selective inhibitors of PI3Ks, we have developed a TR-FRET assay that uses directly labeled reagents.  The assay makes use of the high affinity binding of phosphoinositides to a pleckstrin homol. (PH) domain in the general receptor for phosphoinositides 1 (Grp1) protein.  It monitors PIP3 produced from the enzymic reaction by measuring its competition with Bodipy-FL-labeled PIP3 for binding to terbium chelate-labeled Grp1.  By using directly labeled reagents, this assay configuration offers higher sensitivity and faster binding/dissocn. kinetics than existing non-radioactive assays, which are crit. for competitive assay formats.  The assay is homogeneous, robust (Z' = 0.88), and simple and, thus, compatible with high throughput screening (HTS) processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3gMlKxLJcJLVg90H21EOLACvtfcHk0lgxKir7LMIDew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVKrtb0%253D&md5=def2c27a291077edddd2047918779826</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F138620706777935360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620706777935360%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BC.%26aulast%3DBowman%26aufirst%3DM.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DWolf%26aufirst%3DS.%2BF.%26atitle%3DA%2520directly%2520labeled%2520TR-FRET%2520assay%2520for%2520monitoring%2520phosphoinositide-3-kinase%2520activity%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2006%26volume%3D9%26spage%3D565%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Olivero, A. G.; Heffron, T.; Berry, L.; Berry, M.; Castanedo, G.; Chang, C.; Dotson, J.; Friedman, L. S.; Goldsmith, R.; Lesnick, J.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Pang, J.; Peterson, D.; Prior, W. W.; Salphati, L.; Sampath, D.; Sutherlin, D.; Tsui, V.; Ultsch, M.; Wang, S.; Wiesmann, C.; Wong, S.; Zhu, B.-Y.; Chuckowree, I.; Folkes, A.; Shuttleworth, S.</span><span> </span><span class="NLM_article-title">Design and synthesis of dual PI3K/mTOR Inhibitors</span>.  <span class="citation_source-book">Proceedings of the 100th Annual Meeting of the American Association for Cancer Research</span>, Denver, CO, Apr 18−22, 2009; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Abstract 2707.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+G.+Olivero&author=T.+Heffron&author=L.+Berry&author=M.+Berry&author=G.+Castanedo&author=C.+Chang&author=J.+Dotson&author=L.+S.+Friedman&author=R.+Goldsmith&author=J.+Lesnick&author=C.+Lewis&author=S.+Mathieu&author=J.+Nonomiya&author=J.+Pang&author=D.+Peterson&author=W.+W.+Prior&author=L.+Salphati&author=D.+Sampath&author=D.+Sutherlin&author=V.+Tsui&author=M.+Ultsch&author=S.+Wang&author=C.+Wiesmann&author=S.+Wong&author=B.-Y.+Zhu&author=I.+Chuckowree&author=A.+Folkes&author=S.+Shuttleworth&title=Proceedings+of+the+100th+Annual+Meeting+of+the+American+Association+for+Cancer+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual%2520PI3K%252FmTOR%2520Inhibitors%26btitle%3DProceedings%2520of%2520the%2520100th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%26pub%3DAACR%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Golas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm9014982&amp;key=12543790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm9014982&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Krsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=375-381&author=J.+M.+Golasauthor=K.+Arndtauthor=C.+Etienneauthor=J.+Lucasauthor=D.+Nardinauthor=J.+Gibbonsauthor=P.+Frostauthor=F.+Yeauthor=D.+H.+Boschelliauthor=F.+Boschelli&title=SKI-606%2C+a+4-anilino-3-quinolinecarbonitrile+dual+inhibitor+of+Src+and+Abl+kinases%2C+is+a+potent+antiproliferative+agent+against+chronic+myelogenous+leukemia+cells+in+culture+and+causes+regression+of+K562+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice</span></div><div class="casAuthors">Golas, Jennifer M.; Arndt, Kim; Etienne, Carlo; Lucas, Judy; Nardin, Danielle; Gibbons, James; Frost, Philip; Ye, Fei; Boschelli, Diane H.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">375-381</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive tyrosine kinase activity of Bcr-Abl promotes proliferation and survival of chronic myelogenous leukemia (CML) cells.  Inhibition of Bcr-Abl tyrosine kinase activity or signaling proteins activated by Bcr-Abl in CML cells blocks proliferation and causes apoptotic cell death.  The selective Abl kinase inhibitor, STI-571 (marketed as Gleevec), is toxic to CML cells in culture, causes regression of CML tumors in nude mice, and is currently used to treat CML patients.  Here we describe a p.o. active, dual Src/Abl kinase inhibitor with potent antiproliferative activity against CML cells in culture.  This 4-anilino-3-quinolinecarbonitrile (SKI-606) ablates tyrosine phosphorylation of Bcr-Abl in CML cells and of v-Abl expressed in fibroblasts.  SKI-606 inhibits phosphorylation of cellular proteins, including STAT5, at concns. that inhibit proliferation in CML cells.  Phosphorylation of the autoactivation site of the Src family kinases Lyn and/or Hck is also reduced by treatment with SKI-606.  Once daily oral administration of this compd. at 100 mg/kg for 5 days causes complete regression of large K562 xenografts in nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ0DM9Z0QjjLVg90H21EOLACvtfcHk0ljsrHmGWeuU6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Krsg%253D%253D&md5=e7b5e5ffee0238543dc9c31b7e86b3d2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGolas%26aufirst%3DJ.%2BM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DNardin%26aufirst%3DD.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DSKI-606%252C%2520a%25204-anilino-3-quinolinecarbonitrile%2520dual%2520inhibitor%2520of%2520Src%2520and%2520Abl%2520kinases%252C%2520is%2520a%2520potent%2520antiproliferative%2520agent%2520against%2520chronic%2520myelogenous%2520leukemia%2520cells%2520in%2520culture%2520and%2520causes%2520regression%2520of%2520K562%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D375%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 50 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Aimie
E. Garces, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Stocks</span>. </span><span class="cited-content_cbyCitation_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4815-4850. <a href="https://doi.org/10.1021/acs.jmedchem.8b01492" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DClass%252B1%252BPI3K%252BClinical%252BCandidates%252Band%252BRecent%252BInhibitor%252BDesign%252BStrategies%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DGarces%26aufirst%3DAimie%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D25092018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4815%26epage%3D4850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Yu, Ning Li, Chengde Wu, Amy Guan, Yi Li, Zhengang Peng, Miao He, Jie Li, Zhen Gong, Lei Huang, Bo Gao, Dongling Hao, Jikui Sun, Yan Pan, Liang Shen, Chichung Chan, Xiulian Lu, Hongyu Yuan, Yongguo Li, Jian Li, <span class="NLM_string-name hlFld-ContribAuthor">Shuhui Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (3)
                                     , 256-261. <a href="https://doi.org/10.1021/acsmedchemlett.8b00002" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00002%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPyridopyrimidinones%252Bas%252BPotent%252Band%252BOrally%252BActive%252BDual%252BInhibitors%252Bof%252BPI3K%25252FmTOR%26aulast%3DYu%26aufirst%3DTao%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03012018%26date%3D27022018%26date%3D28022018%26date%3D27022018%26volume%3D9%26issue%3D3%26spage%3D256%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander Lee  Satz</span>, <span class="hlFld-ContribAuthor ">Jianping  Cai</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Robert  Goodnow</span>, <span class="hlFld-ContribAuthor ">Felix  Gruber</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Kowalczyk</span>, <span class="hlFld-ContribAuthor ">Ann  Petersen</span>, <span class="hlFld-ContribAuthor ">Goli  Naderi-Oboodi</span>, <span class="hlFld-ContribAuthor ">Lucja  Orzechowski</span>, and <span class="hlFld-ContribAuthor ">Quentin  Strebel</span>  . </span><span class="cited-content_cbyCitation_article-title">DNA Compatible Multistep Synthesis and Applications to DNA Encoded Libraries. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2015,</strong> <em>26 </em>
                                    (8)
                                     , 1623-1632. <a href="https://doi.org/10.1021/acs.bioconjchem.5b00239" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.5b00239</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.5b00239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.5b00239%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DDNA%252BCompatible%252BMultistep%252BSynthesis%252Band%252BApplications%252Bto%252BDNA%252BEncoded%252BLibraries%26aulast%3DSatz%26aufirst%3DAlexander%2BLee%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D28042015%26date%3D26052015%26date%3D10072015%26date%3D19082015%26date%3D29052015%26volume%3D26%26issue%3D8%26spage%3D1623%26epage%3D1632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingping  Tian</span>, <span class="hlFld-ContribAuthor ">Ursula  Hoffmann</span>, <span class="hlFld-ContribAuthor ">Theresa  Humphries</span>, <span class="hlFld-ContribAuthor ">Zhigang  Cheng</span>, <span class="hlFld-ContribAuthor ">Pirmin  Hidber</span>, <span class="hlFld-ContribAuthor ">Herbert  Yajima</span>, <span class="hlFld-ContribAuthor ">Maud  Guillemot-Plass</span>, <span class="hlFld-ContribAuthor ">Jane  Li</span>, <span class="hlFld-ContribAuthor ">Ulrike  Bromberger</span>, <span class="hlFld-ContribAuthor ">Srinivasan  Babu</span>, <span class="hlFld-ContribAuthor ">David  Askin</span>, and <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>  . </span><span class="cited-content_cbyCitation_article-title">A Practical, Protecting-Group-Free Synthesis of a PI3K/mTOR Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2015,</strong> <em>19 </em>
                                    (3)
                                     , 416-426. <a href="https://doi.org/10.1021/op500366s" title="DOI URL">https://doi.org/10.1021/op500366s</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/op500366s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fop500366s%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DA%252BPractical%25252C%252BProtecting-Group-Free%252BSynthesis%252Bof%252Ba%252BPI3K%25252FmTOR%252BInhibitor%26aulast%3DTian%26aufirst%3DQingping%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D24112014%26date%3D24022015%26date%3D20032015%26date%3D13022015%26volume%3D19%26issue%3D3%26spage%3D416%26epage%3D426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Andrs</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>, <span class="hlFld-ContribAuthor ">Daniel  Jun</span>, <span class="hlFld-ContribAuthor ">Zdenek  Hodny</span>, <span class="hlFld-ContribAuthor ">Jiri  Bartek</span>, and <span class="hlFld-ContribAuthor ">Kamil  Kuca</span>  . </span><span class="cited-content_cbyCitation_article-title">Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (1)
                                     , 41-71. <a href="https://doi.org/10.1021/jm501026z" title="DOI URL">https://doi.org/10.1021/jm501026z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501026z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501026z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPhosphatidylinositol%252B3-Kinase%252B%252528PI3K%252529%252Band%252BPhosphatidylinositol%252B3-Kinase-Related%252BKinase%252B%252528PIKK%252529%252BInhibitors%25253A%252BImportance%252Bof%252Bthe%252BMorpholine%252BRing%26aulast%3DAndrs%26aufirst%3DMartin%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D08072014%26date%3D05122014%26date%3D08012015%26date%3D11112014%26volume%3D58%26issue%3D1%26spage%3D41%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel P.  Sutherlin</span>, <span class="hlFld-ContribAuthor ">Linda  Bao</span>, <span class="hlFld-ContribAuthor ">Megan  Berry</span>, <span class="hlFld-ContribAuthor ">Georgette  Castanedo</span>, <span class="hlFld-ContribAuthor ">Irina  Chuckowree</span>, <span class="hlFld-ContribAuthor ">Jenna  Dotson</span>, <span class="hlFld-ContribAuthor ">Adrian  Folks</span>, <span class="hlFld-ContribAuthor ">Lori  Friedman</span>, <span class="hlFld-ContribAuthor ">Richard  Goldsmith</span>, <span class="hlFld-ContribAuthor ">Janet  Gunzner</span>, <span class="hlFld-ContribAuthor ">Timothy  Heffron</span>, <span class="hlFld-ContribAuthor ">John  Lesnick</span>, <span class="hlFld-ContribAuthor ">Cristina  Lewis</span>, <span class="hlFld-ContribAuthor ">Simon  Mathieu</span>, <span class="hlFld-ContribAuthor ">Jeremy  Murray</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Jodie  Pang</span>, <span class="hlFld-ContribAuthor ">Niel  Pegg</span>, <span class="hlFld-ContribAuthor ">Wei Wei  Prior</span>, <span class="hlFld-ContribAuthor ">Lionel  Rouge</span>, <span class="hlFld-ContribAuthor ">Laurent  Salphati</span>, <span class="hlFld-ContribAuthor ">Deepak  Sampath</span>, <span class="hlFld-ContribAuthor ">Qingping  Tian</span>, <span class="hlFld-ContribAuthor ">Vickie  Tsui</span>, <span class="hlFld-ContribAuthor ">Nan Chi  Wan</span>, <span class="hlFld-ContribAuthor ">Shumei  Wang</span>, <span class="hlFld-ContribAuthor ">BinQing  Wei</span>, <span class="hlFld-ContribAuthor ">Christian  Wiesmann</span>, <span class="hlFld-ContribAuthor ">Ping  Wu</span>, <span class="hlFld-ContribAuthor ">Bing-Yan  Zhu</span>, and <span class="hlFld-ContribAuthor ">Alan  Olivero</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (21)
                                     , 7579-7587. <a href="https://doi.org/10.1021/jm2009327" title="DOI URL">https://doi.org/10.1021/jm2009327</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm2009327%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BAvailable%252BClass%252BI%252BPhosphatidylinositol%252B3-Kinase%252B%252528PI3K%252529%25252FMammalian%252BTarget%252Bof%252BRapamycin%252B%252528mTOR%252529%252BKinase%252BInhibitor%252B%252528GDC-0980%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BCancer%26aulast%3DSutherlin%26aufirst%3DDaniel%2BP.%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D13072011%26date%3D07102011%26date%3D10112011%26volume%3D54%26issue%3D21%26spage%3D7579%26epage%3D7587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zecheng  Chen</span>, <span class="hlFld-ContribAuthor ">Aranapakam M.  Venkatesan</span>, <span class="hlFld-ContribAuthor ">Christoph M.  Dehnhardt</span>, <span class="hlFld-ContribAuthor ">Semiramis  Ayral-Kaloustian</span>, <span class="hlFld-ContribAuthor ">Natasja  Brooijmans</span>, <span class="hlFld-ContribAuthor ">Robert  Mallon</span>, <span class="hlFld-ContribAuthor ">Larry  Feldberg</span>, <span class="hlFld-ContribAuthor ">Irwin  Hollander</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Ker  Yu</span>, <span class="hlFld-ContribAuthor ">Fangming  Kong</span> and <span class="hlFld-ContribAuthor ">Tarek S.  Mansour</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and SAR of Novel 4-Morpholinopyrrolopyrimidine Derivatives as Potent Phosphatidylinositol 3-Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (8)
                                     , 3169-3182. <a href="https://doi.org/10.1021/jm901783v" title="DOI URL">https://doi.org/10.1021/jm901783v</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm901783v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm901783v%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BSAR%252Bof%252BNovel%252B4-Morpholinopyrrolopyrimidine%252BDerivatives%252Bas%252BPotent%252BPhosphatidylinositol%252B3-Kinase%252BInhibitors%26aulast%3DChen%26aufirst%3DZecheng%26date%3D2010%26date%3D2010%26date%3D2009%26date%3D01122009%26date%3D24032010%26date%3D22042010%26volume%3D53%26issue%3D8%26spage%3D3169%26epage%3D3182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aranapakam M.  Venkatesan</span>, <span class="hlFld-ContribAuthor ">Christoph M.  Dehnhardt</span>, <span class="hlFld-ContribAuthor ">Efren  Delos Santos</span>, <span class="hlFld-ContribAuthor ">Zecheng  Chen</span>, <span class="hlFld-ContribAuthor ">Osvaldo  Dos Santos</span>, <span class="hlFld-ContribAuthor ">Semiramis  Ayral-Kaloustian</span>, <span class="hlFld-ContribAuthor ">Gulnaz  Khafizova</span>, <span class="hlFld-ContribAuthor ">Natasja  Brooijmans</span>, <span class="hlFld-ContribAuthor ">Robert  Mallon</span>, <span class="hlFld-ContribAuthor ">Irwin  Hollander</span>, <span class="hlFld-ContribAuthor ">Larry  Feldberg</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Ker  Yu</span>, <span class="hlFld-ContribAuthor ">James  Gibbons</span>, <span class="hlFld-ContribAuthor ">Robert T.  Abraham</span>, <span class="hlFld-ContribAuthor ">Inder  Chaudhary</span> and <span class="hlFld-ContribAuthor ">Tarek S.  Mansour</span>  . </span><span class="cited-content_cbyCitation_article-title">Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (6)
                                     , 2636-2645. <a href="https://doi.org/10.1021/jm901830p" title="DOI URL">https://doi.org/10.1021/jm901830p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm901830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm901830p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBis%252528morpholino-1%25252C3%25252C5-triazine%252529%252BDerivatives%25253A%252BPotent%252BAdenosine%252B5%2525E2%252580%2525B2-Triphosphate%252BCompetitive%252BPhosphatidylinositol-3-kinase%25252FMammalian%252BTarget%252Bof%252BRapamycin%252BInhibitors%25253A%252BDiscovery%252Bof%252BCompound%252B26%252B%252528PKI-587%252529%25252C%252Ba%252BHighly%252BEfficacious%252BDual%252BInhibitor%26aulast%3DVenkatesan%26aufirst%3DAranapakam%2BM.%26date%3D2010%26date%3D2010%26date%3D2009%26date%3D11122009%26date%3D18022010%26date%3D25032010%26volume%3D53%26issue%3D6%26spage%3D2636%26epage%3D2645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Yuan</span>, <span class="hlFld-ContribAuthor ">Huan-Huan  Yang</span>, <span class="hlFld-ContribAuthor ">Kai-Hao  Li</span>, <span class="hlFld-ContribAuthor ">Jun-Ying  Song</span>, <span class="hlFld-ContribAuthor ">Hai-Rong  Lan</span>, <span class="hlFld-ContribAuthor ">Hui-Zhong  Kou</span>. </span><span class="cited-content_cbyCitation_article-title">Novel iron(III) complexes based on 2-hydrazinylpyrimidine derivative: Synthesis, characterization and preliminary evaluation of antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1238 </em>, 130417. <a href="https://doi.org/10.1016/j.molstruc.2021.130417" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130417%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DNovel%252Biron%252528III%252529%252Bcomplexes%252Bbased%252Bon%252B2-hydrazinylpyrimidine%252Bderivative%25253A%252BSynthesis%25252C%252Bcharacterization%252Band%252Bpreliminary%252Bevaluation%252Bof%252Bantitumor%252Bactivity%26aulast%3DYuan%26aufirst%3DJuan%26date%3D2021%26volume%3D1238%26spage%3D130417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Borsari</span>, <span class="hlFld-ContribAuthor ">Martina  De Pascale</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical and Structural Strategies to Selectively Target mTOR Kinase. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1002/cmdc.202100332" title="DOI URL">https://doi.org/10.1002/cmdc.202100332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100332%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DChemical%252Band%252BStructural%252BStrategies%252Bto%252BSelectively%252BTarget%252BmTOR%252BKinase%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chenhao  Xu</span>, <span class="hlFld-ContribAuthor ">Wenjuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Guanjun  Dong</span>, <span class="hlFld-ContribAuthor ">Hui  Qiao</span>, <span class="hlFld-ContribAuthor ">Jiadi  Peng</span>, <span class="hlFld-ContribAuthor ">Pengfei  Jia</span>, <span class="hlFld-ContribAuthor ">Yuhao  Li</span>, <span class="hlFld-ContribAuthor ">Hongmin  Liu</span>, <span class="hlFld-ContribAuthor ">Kai  Sun</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives containing hydrazone fragment as potent and selective anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>105 </em>, 104424. <a href="https://doi.org/10.1016/j.bioorg.2020.104424" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104424</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104424%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252B%25255B1%25252C2%25252C3%25255Dtriazolo%25255B4%25252C5-d%25255Dpyrimidine%252Bderivatives%252Bcontaining%252Bhydrazone%252Bfragment%252Bas%252Bpotent%252Band%252Bselective%252Banticancer%252Bagents%26aulast%3DXu%26aufirst%3DChenhao%26date%3D2020%26volume%3D105%26spage%3D104424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mai A.  Mansour</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Hatem M.  Gaber</span>, <span class="hlFld-ContribAuthor ">Khaled A. M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Elaborating piperazinyl-furopyrimidine based scaffolds as phosphoinositol-3-kinase enzyme alpha (PI3Kα) inhibitors to combat pancreatic cancer. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (53)
                                     , 32103-32112. <a href="https://doi.org/10.1039/D0RA06428A" title="DOI URL">https://doi.org/10.1039/D0RA06428A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA06428A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA06428A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DElaborating%252Bpiperazinyl-furopyrimidine%252Bbased%252Bscaffolds%252Bas%252Bphosphoinositol-3-kinase%252Benzyme%252Balpha%252B%252528PI3K%2525CE%2525B1%252529%252Binhibitors%252Bto%252Bcombat%252Bpancreatic%252Bcancer%26aulast%3DMansour%26aufirst%3DMai%2BA.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D53%26spage%3D32103%26epage%3D32112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huanhuan  Yang</span>, <span class="hlFld-ContribAuthor ">Fanyu  Shi</span>, <span class="hlFld-ContribAuthor ">Qingqing  Xu</span>, <span class="hlFld-ContribAuthor ">Jinghai  Wang</span>, <span class="hlFld-ContribAuthor ">Ai-Ping  Xing</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal structure of (E)-2-((2-(pyrimidin-2-yl)hydrazono)methyl)quinolin-1-ium perchlorate – methanol (1/1), C15H16N5O5Cl. </span><span class="cited-content_cbyCitation_journal-name">Zeitschrift für Kristallographie - New Crystal Structures</span><span> <strong>2020,</strong> <em>235 </em>
                                    (3)
                                     , 635-637. <a href="https://doi.org/10.1515/ncrs-2019-0873" title="DOI URL">https://doi.org/10.1515/ncrs-2019-0873</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/ncrs-2019-0873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fncrs-2019-0873%26sid%3Dliteratum%253Aachs%26jtitle%3DZeitschrift%2520f%25C3%25BCr%2520Kristallographie%2520-%2520New%2520Crystal%2520Structures%26atitle%3DCrystal%252Bstructure%252Bof%252B%252528E%252529-2-%252528%2525282-%252528pyrimidin-2-yl%252529hydrazono%252529methyl%252529quinolin-1-ium%252Bperchlorate%252B%2525E2%252580%252593%252Bmethanol%252B%2525281%25252F1%252529%25252C%252BC15H16N5O5Cl%26aulast%3DYang%26aufirst%3DHuanhuan%26date%3D2020%26volume%3D235%26issue%3D3%26spage%3D635%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tobie D.  Lee</span>, <span class="hlFld-ContribAuthor ">Olivia W.  Lee</span>, <span class="hlFld-ContribAuthor ">Kyle R.  Brimacombe</span>, <span class="hlFld-ContribAuthor ">Lu  Chen</span>, <span class="hlFld-ContribAuthor ">Rajarshi  Guha</span>, <span class="hlFld-ContribAuthor ">Sabrina  Lusvarghi</span>, <span class="hlFld-ContribAuthor ">Bethilehem G.  Tebase</span>, <span class="hlFld-ContribAuthor ">Carleen  Klumpp-Thomas</span>, <span class="hlFld-ContribAuthor ">Robert W.  Robey</span>, <span class="hlFld-ContribAuthor ">Suresh V.  Ambudkar</span>, <span class="hlFld-ContribAuthor ">Min  Shen</span>, <span class="hlFld-ContribAuthor ">Michael M.  Gottesman</span>, <span class="hlFld-ContribAuthor ">Matthew D.  Hall</span>. </span><span class="cited-content_cbyCitation_article-title">A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmacology</span><span> <strong>2019,</strong> <em>96 </em>
                                    (5)
                                     , 629-640. <a href="https://doi.org/10.1124/mol.119.115964" title="DOI URL">https://doi.org/10.1124/mol.119.115964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/mol.119.115964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fmol.119.115964%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmacology%26atitle%3DA%252BHigh-Throughput%252BScreen%252Bof%252Ba%252BLibrary%252Bof%252BTherapeutics%252BIdentifies%252BCytotoxic%252BSubstrates%252Bof%252BP-glycoprotein%26aulast%3DLee%26aufirst%3DTobie%2BD.%26date%3D2019%26date%3D2019%26volume%3D96%26issue%3D5%26spage%3D629%26epage%3D640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lide  Yu</span>, <span class="hlFld-ContribAuthor ">Qinqin  Wang</span>, <span class="hlFld-ContribAuthor ">Caolin  Wang</span>, <span class="hlFld-ContribAuthor ">Binliang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Yuanying  Fang</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (19)
                                     , 3422. <a href="https://doi.org/10.3390/molecules24193422" title="DOI URL">https://doi.org/10.3390/molecules24193422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24193422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24193422%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BThienopyrimidine%252BDerivatives%252Bas%252BPI3K%2525CE%2525B1%252BInhibitors%26aulast%3DYu%26aufirst%3DLide%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D19%26spage%3D3422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guoyi  Yan</span>, <span class="hlFld-ContribAuthor ">Chunlan  Pu</span>, <span class="hlFld-ContribAuthor ">Suke  Lan</span>, <span class="hlFld-ContribAuthor ">Xinxin  Zhong</span>, <span class="hlFld-ContribAuthor ">Meng  Zhou</span>, <span class="hlFld-ContribAuthor ">Xueyan  Hou</span>, <span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Huifang  Shan</span>, <span class="hlFld-ContribAuthor ">Lifeng  Zhao</span>, <span class="hlFld-ContribAuthor ">Rui  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 667-686. <a href="https://doi.org/10.1016/j.ejmech.2019.06.021" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-phenyl-2H-benzo%25255Bb%25255D%25255B1%25252C4%25255Doxazin-3%2525284H%252529-one%252Bderivatives%252Bas%252Bpotent%252Band%252Borally%252Bactive%252BPI3K%25252FmTOR%252Bdual%252Binhibitors%26aulast%3DYan%26aufirst%3DGuoyi%26date%3D2019%26volume%3D178%26spage%3D667%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guixin  Yuan</span>, <span class="hlFld-ContribAuthor ">Zhen  Lian</span>, <span class="hlFld-ContribAuthor ">Qian  Liu</span>, <span class="hlFld-ContribAuthor ">Xixi  Lin</span>, <span class="hlFld-ContribAuthor ">Dantao  Xie</span>, <span class="hlFld-ContribAuthor ">Fangming  Song</span>, <span class="hlFld-ContribAuthor ">Xinjia  Wang</span>, <span class="hlFld-ContribAuthor ">Siyuan  Shao</span>, <span class="hlFld-ContribAuthor ">Bo  Zhou</span>, <span class="hlFld-ContribAuthor ">Chen  Li</span>, <span class="hlFld-ContribAuthor ">Muyan  Li</span>, <span class="hlFld-ContribAuthor ">Guanfeng  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>443 </em>, 135-144. <a href="https://doi.org/10.1016/j.canlet.2018.11.038" title="DOI URL">https://doi.org/10.1016/j.canlet.2018.11.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2018.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2018.11.038%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DPhosphatidyl%252Binositol%252B3-kinase%252B%252528PI3K%252529-mTOR%252Binhibitor%252BPKI-402%252Binhibits%252Bbreast%252Bcancer%252Binduced%252Bosteolysis%26aulast%3DYuan%26aufirst%3DGuixin%26date%3D2019%26volume%3D443%26spage%3D135%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mayur K.  Vekariya</span>, <span class="hlFld-ContribAuthor ">Rajesh H.  Vekariya</span>, <span class="hlFld-ContribAuthor ">Kinjal D.  Patel</span>, <span class="hlFld-ContribAuthor ">Nirav P.  Raval</span>, <span class="hlFld-ContribAuthor ">Prapti U.  Shah</span>, <span class="hlFld-ContribAuthor ">Dhanji P.  Rajani</span>, <span class="hlFld-ContribAuthor ">Nisha K.  Shah</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimidine-Pyrazole Hybrids as Morpholinopyrimidine-Based Pyrazole Carboxamides: Synthesis, Characterisation, Docking, ADMET Study and Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2018,</strong> <em>3 </em>
                                    (24)
                                     , 6998-7008. <a href="https://doi.org/10.1002/slct.201801011" title="DOI URL">https://doi.org/10.1002/slct.201801011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201801011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201801011%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DPyrimidine-Pyrazole%252BHybrids%252Bas%252BMorpholinopyrimidine-Based%252BPyrazole%252BCarboxamides%25253A%252BSynthesis%25252C%252BCharacterisation%25252C%252BDocking%25252C%252BADMET%252BStudy%252Band%252BBiological%252BEvaluation%26aulast%3DVekariya%26aufirst%3DMayur%2BK.%26date%3D2018%26date%3D2018%26volume%3D3%26issue%3D24%26spage%3D6998%26epage%3D7008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Supreet  Gaonkar</span>, <span class="hlFld-ContribAuthor ">Mohammed Azharuddin  Savanur</span>, <span class="hlFld-ContribAuthor ">Manjunath G.  Sunagar</span>, <span class="hlFld-ContribAuthor ">Bijesh  Puthusseri</span>, <span class="hlFld-ContribAuthor ">Narahari  Deshapande</span>, <span class="hlFld-ContribAuthor ">Afra A.  Nadaf</span>, <span class="hlFld-ContribAuthor ">Imtiyaz Ahmed M.  Khazi</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the potential of newly synthesized 4-methyl-6-morpholino-pyrimidine derivatives as antiproliferative agents. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2018,</strong> <em>42 </em>
                                    (4)
                                     , 2790-2803. <a href="https://doi.org/10.1039/C7NJ04157H" title="DOI URL">https://doi.org/10.1039/C7NJ04157H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7NJ04157H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7NJ04157H%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DExploring%252Bthe%252Bpotential%252Bof%252Bnewly%252Bsynthesized%252B4-methyl-6-morpholino-pyrimidine%252Bderivatives%252Bas%252Bantiproliferative%252Bagents%26aulast%3DGaonkar%26aufirst%3DSupreet%26date%3D2018%26date%3D2018%26volume%3D42%26issue%3D4%26spage%3D2790%26epage%3D2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Costantino</span>, <span class="hlFld-ContribAuthor ">Daniela  Barlocco</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Approaches to Multitarget Drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 161-205. <a href="https://doi.org/10.1002/9783527674381.ch7" title="DOI URL">https://doi.org/10.1002/9783527674381.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527674381.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527674381.ch7%26sid%3Dliteratum%253Aachs%26atitle%3DDesigning%252BApproaches%252Bto%252BMultitarget%252BDrugs%26aulast%3DCostantino%26aufirst%3DLuca%26date%3D2017%26date%3D2017%26spage%3D161%26epage%3D205%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DDrug%252BSelectivity%26aulast%3DHandler%26aufirst%3DNorbert%26date%3D2017%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chengying  Xie</span>, <span class="hlFld-ContribAuthor ">Xiangling  Chen</span>, <span class="hlFld-ContribAuthor ">Mingyue  Zheng</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Liu</span>, <span class="hlFld-ContribAuthor ">Hongbin  Wang</span>, <span class="hlFld-ContribAuthor ">Liguang  Lou</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (64)
                                     , 107977-107990. <a href="https://doi.org/10.18632/oncotarget.22439" title="DOI URL">https://doi.org/10.18632/oncotarget.22439</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.22439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.22439%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DPharmacologic%252Bcharacterization%252Bof%252BSHR8443%25252C%252Ba%252Bnovel%252Bdual%252Binhibitor%252Bof%252Bphosphatidylinositol%252B3-kinase%252Band%252Bmammalian%252Btarget%252Bof%252Brapamycin%26aulast%3DXie%26aufirst%3DChengying%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D64%26spage%3D107977%26epage%3D107990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-zhu  Wan</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Guan-lian  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin-guang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (4)
                                     , 7181-7200. <a href="https://doi.org/10.18632/oncotarget.12742" title="DOI URL">https://doi.org/10.18632/oncotarget.12742</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.12742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.12742%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DRecent%252Bdevelopment%252Bof%252BATP-competitive%252Bsmall%252Bmolecule%252Bphosphatidylinostitol-3-kinase%252Binhibitors%252Bas%252Banticancer%252Bagents%26aulast%3DLiu%26aufirst%3DYu%26date%3D2017%26date%3D2016%26volume%3D8%26issue%3D4%26spage%3D7181%26epage%3D7200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A Elisa  Pasqua</span>, <span class="hlFld-ContribAuthor ">B.  Wilding</span>, <span class="hlFld-ContribAuthor ">M.D.  Cheeseman</span>, <span class="hlFld-ContribAuthor ">K.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 202-280. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12395-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12395-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12395-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12395-9%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252BProtein%252BSynthesis%25252C%252BFolding%25252C%252Band%252BDegradation%252BPathways%252Bin%252BCancer%26aulast%3DPasqua%26aufirst%3DA%2BElisa%26date%3D2017%26spage%3D202%26epage%3D280%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mansoore  Igei</span>, <span class="hlFld-ContribAuthor ">Mehdi  Bakavoli</span>, <span class="hlFld-ContribAuthor ">Ali  Shiri</span>, <span class="hlFld-ContribAuthor ">Zahra  Ebrahimpour</span>, <span class="hlFld-ContribAuthor ">Hamid  Azizollahi</span>, <span class="hlFld-ContribAuthor ">Hamid  Beyzaei</span>, <span class="hlFld-ContribAuthor ">Mohammadreza  Moghaddam-Manesh</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Some New Pyrimido[4,5-e]Tetrazolo[5,1-b][1,3,4]Thiadiazine Derivatives via an S–N Type Smiles Rearrangement and their Antibacterial Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2016,</strong> <em>40 </em>
                                    (10)
                                     , 628-632. <a href="https://doi.org/10.3184/174751916X14742893137631" title="DOI URL">https://doi.org/10.3184/174751916X14742893137631</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3184/174751916X14742893137631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3184%2F174751916X14742893137631%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DSynthesis%252Bof%252BSome%252BNew%252BPyrimido%25255B4%25252C5-e%25255DTetrazolo%25255B5%25252C1-b%25255D%25255B1%25252C3%25252C4%25255DThiadiazine%252BDerivatives%252Bvia%252Ban%252BS%2525E2%252580%252593N%252BType%252BSmiles%252BRearrangement%252Band%252Btheir%252BAntibacterial%252BEvaluation%26aulast%3DIgei%26aufirst%3DMansoore%26date%3D2016%26date%3D2016%26volume%3D40%26issue%3D10%26spage%3D628%26epage%3D632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Lei</span>, <span class="hlFld-ContribAuthor ">Chengyu  Sun</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Qinqin  Wang</span>, <span class="hlFld-ContribAuthor ">Yiqiang  OuYang</span>, <span class="hlFld-ContribAuthor ">Chen  Chen</span>, <span class="hlFld-ContribAuthor ">Hui  Xia</span>, <span class="hlFld-ContribAuthor ">Linxiao  Wang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5 H -thiopyrano[4,3- d ]pyrimidine derivatives as dual PI3Kα/mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>116 </em>, 27-35. <a href="https://doi.org/10.1016/j.ejmech.2016.03.033" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.03.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.03.033%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bdocking%252Bstudies%252Bof%252Bnovel%252B2-substituted-4-morpholino-7%25252C8-dihydro-5%252BH%252B-thiopyrano%25255B4%25252C3-%252Bd%252B%25255Dpyrimidine%252Bderivatives%252Bas%252Bdual%252BPI3K%2525CE%2525B1%25252FmTOR%252Binhibitors%26aulast%3DLei%26aufirst%3DFei%26date%3D2016%26volume%3D116%26spage%3D27%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia-Lin  Guo</span>, <span class="hlFld-ContribAuthor ">Yun-Yong  Liu</span>, <span class="hlFld-ContribAuthor ">Ya-Zhong  Pei</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 3-(piperidin-4-yl)isoxazolo[4,5-d]pyrimidine derivatives as novel PI3Kδ inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2015,</strong> <em>26 </em>
                                    (10)
                                     , 1283-1288. <a href="https://doi.org/10.1016/j.cclet.2015.05.041" title="DOI URL">https://doi.org/10.1016/j.cclet.2015.05.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2015.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2015.05.041%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B3-%252528piperidin-4-yl%252529isoxazolo%25255B4%25252C5-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnovel%252BPI3K%2525CE%2525B4%252Binhibitors%26aulast%3DGuo%26aufirst%3DJia-Lin%26date%3D2015%26volume%3D26%26issue%3D10%26spage%3D1283%26epage%3D1288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prinka  Singla</span>, <span class="hlFld-ContribAuthor ">Vijay  Luxami</span>, <span class="hlFld-ContribAuthor ">Kamaldeep  Paul</span>. </span><span class="cited-content_cbyCitation_article-title">Triazine as a promising scaffold for its versatile biological behavior. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>102 </em>, 39-57. <a href="https://doi.org/10.1016/j.ejmech.2015.07.037" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.07.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.07.037%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTriazine%252Bas%252Ba%252Bpromising%252Bscaffold%252Bfor%252Bits%252Bversatile%252Bbiological%252Bbehavior%26aulast%3DSingla%26aufirst%3DPrinka%26date%3D2015%26volume%3D102%26spage%3D39%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tayebe  Asghari</span>, <span class="hlFld-ContribAuthor ">Mehdi  Bakavoli</span>, <span class="hlFld-ContribAuthor ">Mohammad  Rahimizadeh</span>, <span class="hlFld-ContribAuthor ">Hossein  Eshghi</span>, <span class="hlFld-ContribAuthor ">Sattar  Saberi</span>, <span class="hlFld-ContribAuthor ">Azam  Karimian</span>, <span class="hlFld-ContribAuthor ">Farzin  Hadizadeh</span>, <span class="hlFld-ContribAuthor ">Moreteza  Ghandadi</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of a New Series of 3,5-bis((5-bromo-6-methyl-2-
              t
              -aminopyrimidin-4-yl)thio)-4
              H
              -1,2,4-triazol-4-amines and their Cyclized Products ‘Pyrimidinylthio Pyrimidotriazolothiadiazines’ as 15- Lipo-Oxygenase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2015,</strong> <em>85 </em>
                                    (2)
                                     , 216-224. <a href="https://doi.org/10.1111/cbdd.12375" title="DOI URL">https://doi.org/10.1111/cbdd.12375</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12375%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252Ba%252BNew%252BSeries%252Bof%252B3%25252C5-bis%252528%2525285-bromo-6-methyl-2-%252Bt%252B-aminopyrimidin-4-yl%252529thio%252529-4%252BH%252B-1%25252C2%25252C4-triazol-4-amines%252Band%252Btheir%252BCyclized%252BProducts%252B%2525E2%252580%252598Pyrimidinylthio%252BPyrimidotriazolothiadiazines%2525E2%252580%252599%252Bas%252B15-%252BLipo-Oxygenase%252BInhibitors%26aulast%3DAsghari%26aufirst%3DTayebe%26date%3D2015%26date%3D2014%26volume%3D85%26issue%3D2%26spage%3D216%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierfausto  Seneci</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Unselective Autophagy of Cellular Aggregates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 95-133. <a href="https://doi.org/10.1016/B978-0-12-801944-3.00004-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-801944-3.00004-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-801944-3.00004-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-801944-3.00004-7%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252BUnselective%252BAutophagy%252Bof%252BCellular%252BAggregates%26aulast%3DSeneci%26aufirst%3DPierfausto%26date%3D2015%26spage%3D95%26epage%3D133%26pub%3DElsevier%26atitle%3DChemical%252BModulators%252Bof%252BProtein%252BMisfolding%252Band%252BNeurodegenerative%252BDisease%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teng  Shao</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Jian-Gang  Chen</span>, <span class="hlFld-ContribAuthor ">Xiao-Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Huan  Li</span>, <span class="hlFld-ContribAuthor ">Yi-Ping  Li</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Guang-De  Yang</span>, <span class="hlFld-ContribAuthor ">Qi-Bing  Mei</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>75 </em>, 96-105. <a href="https://doi.org/10.1016/j.ejmech.2014.01.053" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.01.053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.01.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.01.053%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-methoxy-3-phenylsulfonamino-5-%252528quinazolin-6-yl%252Bor%252Bquinolin-6-yl%252529benzamides%252Bas%252Bnovel%252BPI3K%252Binhibitors%252Band%252Banticancer%252Bagents%252Bby%252Bbioisostere%26aulast%3DShao%26aufirst%3DTeng%26date%3D2014%26volume%3D75%26spage%3D96%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Gordon W.  Rewcastle</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of the Phosphatidylinositol 3-Kinase Pathway. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 449-478. <a href="https://doi.org/10.1016/B978-0-12-396521-9.00015-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-396521-9.00015-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-396521-9.00015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-396521-9.00015-2%26sid%3Dliteratum%253Aachs%26atitle%3DInhibitors%252Bof%252Bthe%252BPhosphatidylinositol%252B3-Kinase%252BPathway%26aulast%3DDenny%26aufirst%3DWilliam%2BA.%26date%3D2014%26spage%3D449%26epage%3D478%26pub%3DElsevier%26atitle%3DCancer%252BDrug%252BDesign%252Band%252BDiscovery%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenjuan  Yang</span>, <span class="hlFld-ContribAuthor ">Mao  Shu</span>, <span class="hlFld-ContribAuthor ">Yuanqiang  Wang</span>, <span class="hlFld-ContribAuthor ">Rui  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Hu</span>, <span class="hlFld-ContribAuthor ">Lingxin  Meng</span>, <span class="hlFld-ContribAuthor ">Zhihua  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR and docking studies of 3-Pyridine heterocyclic derivatives as potent PI3K/mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2013,</strong> <em>1054-1055 </em>, 107-116. <a href="https://doi.org/10.1016/j.molstruc.2013.09.049" title="DOI URL">https://doi.org/10.1016/j.molstruc.2013.09.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2013.09.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2013.09.049%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3D3D-QSAR%252Band%252Bdocking%252Bstudies%252Bof%252B3-Pyridine%252Bheterocyclic%252Bderivatives%252Bas%252Bpotent%252BPI3K%25252FmTOR%252Binhibitors%26aulast%3DYang%26aufirst%3DWenjuan%26date%3D2013%26volume%3D1054-1055%26spage%3D107%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2013,</strong> <em>8 </em>
                                    (8)
                                     , 991-1012. <a href="https://doi.org/10.1517/17460441.2013.800479" title="DOI URL">https://doi.org/10.1517/17460441.2013.800479</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17460441.2013.800479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17460441.2013.800479%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DFurthering%252Bthe%252Bdesign%252Band%252Bthe%252Bdiscovery%252Bof%252Bsmall%252Bmolecule%252BATP-competitive%252BmTOR%252Binhibitors%252Bas%252Ban%252Beffective%252Bcancer%252Btreatment%26aulast%3DLv%26aufirst%3DXiaoqing%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D8%26spage%3D991%26epage%3D1012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Xuan</span>, <span class="hlFld-ContribAuthor ">Wen  Ding</span>, <span class="hlFld-ContribAuthor ">Hong-xiang  Hui</span>, <span class="hlFld-ContribAuthor ">San-qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and cytotoxic activity of diaryl urea derivatives with a 4-methylpiperazinylcarbonyl moiety. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2013,</strong> <em>22 </em>
                                    (8)
                                     , 3857-3862. <a href="https://doi.org/10.1007/s00044-012-0398-y" title="DOI URL">https://doi.org/10.1007/s00044-012-0398-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-012-0398-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-012-0398-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DSynthesis%252Band%252Bcytotoxic%252Bactivity%252Bof%252Bdiaryl%252Burea%252Bderivatives%252Bwith%252Ba%252B4-methylpiperazinylcarbonyl%252Bmoiety%26aulast%3DXuan%26aufirst%3DWei%26date%3D2013%26date%3D2012%26volume%3D22%26issue%3D8%26spage%3D3857%26epage%3D3862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.E.  Korsse</span>, <span class="hlFld-ContribAuthor ">M.P.  Peppelenbosch</span>, <span class="hlFld-ContribAuthor ">W.  van Veelen</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting LKB1 signaling in cancer. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2013,</strong> <em>1835 </em>
                                    (2)
                                     , 194-210. <a href="https://doi.org/10.1016/j.bbcan.2012.12.006" title="DOI URL">https://doi.org/10.1016/j.bbcan.2012.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2012.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DTargeting%252BLKB1%252Bsignaling%252Bin%252Bcancer%26aulast%3DKorsse%26aufirst%3DS.E.%26date%3D2013%26volume%3D1835%26issue%3D2%26spage%3D194%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Wu</span>, <span class="hlFld-ContribAuthor ">Xueyan  Hou</span>, <span class="hlFld-ContribAuthor ">Hao  Luo</span>, <span class="hlFld-ContribAuthor ">Meng  Zhou</span>, <span class="hlFld-ContribAuthor ">Wenjuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenyu  Ding</span>, <span class="hlFld-ContribAuthor ">Rui  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the selectivity of PI3Kα and mTOR inhibitors by 3D-QSAR, molecular dynamics simulations and MM/GBSA binding free energy decomposition. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2013,</strong> <em>4 </em>
                                    (11)
                                     , 1482. <a href="https://doi.org/10.1039/c3md00157a" title="DOI URL">https://doi.org/10.1039/c3md00157a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c3md00157a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc3md00157a%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DExploring%252Bthe%252Bselectivity%252Bof%252BPI3K%2525CE%2525B1%252Band%252BmTOR%252Binhibitors%252Bby%252B3D-QSAR%25252C%252Bmolecular%252Bdynamics%252Bsimulations%252Band%252BMM%25252FGBSA%252Bbinding%252Bfree%252Benergy%252Bdecomposition%26aulast%3DWu%26aufirst%3DFeng%26date%3D2013%26volume%3D4%26issue%3D11%26spage%3D1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ipsita  Pal</span>, <span class="hlFld-ContribAuthor ">Mahitosh  Mandal</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2012,</strong> <em>33 </em>
                                    (12)
                                     , 1441-1458. <a href="https://doi.org/10.1038/aps.2012.72" title="DOI URL">https://doi.org/10.1038/aps.2012.72</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/aps.2012.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Faps.2012.72%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DPI3K%252Band%252BAkt%252Bas%252Bmolecular%252Btargets%252Bfor%252Bcancer%252Btherapy%25253A%252Bcurrent%252Bclinical%252Boutcomes%26aulast%3DPal%26aufirst%3DIpsita%26date%3D2012%26date%3D2012%26volume%3D33%26issue%3D12%26spage%3D1441%26epage%3D1458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinbao  Xiang</span>, <span class="hlFld-ContribAuthor ">Hanghang  Li</span>, <span class="hlFld-ContribAuthor ">Kai  Yang</span>, <span class="hlFld-ContribAuthor ">Lang  Yi</span>, <span class="hlFld-ContribAuthor ">Yongnan  Xu</span>, <span class="hlFld-ContribAuthor ">Qun  Dang</span>, <span class="hlFld-ContribAuthor ">Xu  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of novel 4H-pyrimido[1,6-a]pyrimidines via a one-pot three-component condensation. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2012,</strong> <em>16 </em>
                                    (1)
                                     , 173-181. <a href="https://doi.org/10.1007/s11030-011-9345-y" title="DOI URL">https://doi.org/10.1007/s11030-011-9345-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-011-9345-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-011-9345-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%252Bof%252Bnovel%252B4H-pyrimido%25255B1%25252C6-a%25255Dpyrimidines%252Bvia%252Ba%252Bone-pot%252Bthree-component%252Bcondensation%26aulast%3DXiang%26aufirst%3DJinbao%26date%3D2012%26date%3D2011%26volume%3D16%26issue%3D1%26spage%3D173%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Weiwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Ying  Leng</span>, <span class="hlFld-ContribAuthor ">Guowu  Lin</span>, <span class="hlFld-ContribAuthor ">Shulin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2012,</strong> <em>18 </em>
                                    (1)
                                     , 171-186. <a href="https://doi.org/10.1007/s00894-011-1034-3" title="DOI URL">https://doi.org/10.1007/s00894-011-1034-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-011-1034-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-011-1034-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DA%252Bselectivity%252Bstudy%252Bon%252BmTOR%25252FPI3K%2525CE%2525B1%252Binhibitors%252Bby%252Bhomology%252Bmodeling%252Band%252B3D-QSAR%26aulast%3DRan%26aufirst%3DTing%26date%3D2012%26date%3D2011%26volume%3D18%26issue%3D1%26spage%3D171%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng  Wu</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules targeting phosphoinositide 3-kinases. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2012,</strong> <em>3 </em>
                                    (11)
                                     , 1337. <a href="https://doi.org/10.1039/c2md20044a" title="DOI URL">https://doi.org/10.1039/c2md20044a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c2md20044a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc2md20044a%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DSmall%252Bmolecules%252Btargeting%252Bphosphoinositide%252B3-kinases%26aulast%3DWu%26aufirst%3DPeng%26date%3D2012%26volume%3D3%26issue%3D11%26spage%3D1337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinbao  Xiang</span>, <span class="hlFld-ContribAuthor ">Chao  Geng</span>, <span class="hlFld-ContribAuthor ">Lang  Yi</span>, <span class="hlFld-ContribAuthor ">Qun  Dang</span>, <span class="hlFld-ContribAuthor ">Xu  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of highly substituted 2,3-dihydropyrimido[4,5-d]pyrimidin-4(1H)-ones from 4,6-dichloro-5-formylpyrimidine, amines and aldehydes. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2011,</strong> <em>15 </em>
                                    (4)
                                     , 839-847. <a href="https://doi.org/10.1007/s11030-011-9314-5" title="DOI URL">https://doi.org/10.1007/s11030-011-9314-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-011-9314-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-011-9314-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%252Bof%252Bhighly%252Bsubstituted%252B2%25252C3-dihydropyrimido%25255B4%25252C5-d%25255Dpyrimidin-4%2525281H%252529-ones%252Bfrom%252B4%25252C6-dichloro-5-formylpyrimidine%25252C%252Bamines%252Band%252Baldehydes%26aulast%3DXiang%26aufirst%3DJinbao%26date%3D2011%26date%3D2011%26volume%3D15%26issue%3D4%26spage%3D839%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christoph M.  Dehnhardt</span>, <span class="hlFld-ContribAuthor ">Aranapakam M.  Venkatesan</span>, <span class="hlFld-ContribAuthor ">Zecheng  Chen</span>, <span class="hlFld-ContribAuthor ">Efren  Delos-Santos</span>, <span class="hlFld-ContribAuthor ">Semiramis  Ayral-Kaloustian</span>, <span class="hlFld-ContribAuthor ">Natasja  Brooijmans</span>, <span class="hlFld-ContribAuthor ">Ker  Yu</span>, <span class="hlFld-ContribAuthor ">Irwin  Hollander</span>, <span class="hlFld-ContribAuthor ">Larry  Feldberg</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Robert  Mallon</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (16)
                                     , 4773-4778. <a href="https://doi.org/10.1016/j.bmcl.2011.06.063" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.06.063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.06.063%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252B2-oxatriazines%252Bas%252Bhighly%252Bpotent%252Bpan-PI3K%25252FmTOR%252Bdual%252Binhibitors%26aulast%3DDehnhardt%26aufirst%3DChristoph%2BM.%26date%3D2011%26volume%3D21%26issue%3D16%26spage%3D4773%26epage%3D4778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Mallon</span>, <span class="hlFld-ContribAuthor ">Larry R.  Feldberg</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Inder  Chaudhary</span>, <span class="hlFld-ContribAuthor ">Christoph  Dehnhardt</span>, <span class="hlFld-ContribAuthor ">Efren Delos  Santos</span>, <span class="hlFld-ContribAuthor ">Zecheng  Chen</span>, <span class="hlFld-ContribAuthor ">Osvaldo  dos Santos</span>, <span class="hlFld-ContribAuthor ">Semiramis  Ayral-Kaloustian</span>, <span class="hlFld-ContribAuthor ">Aranapakam  Venkatesan</span>, <span class="hlFld-ContribAuthor ">Irwin  Hollander</span>. </span><span class="cited-content_cbyCitation_article-title">Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2011,</strong> <em>17 </em>
                                    (10)
                                     , 3193-3203. <a href="https://doi.org/10.1158/1078-0432.CCR-10-1694" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-10-1694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-10-1694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-10-1694%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DAntitumor%252BEfficacy%252Bof%252BPKI-587%25252C%252Ba%252BHighly%252BPotent%252BDual%252BPI3K%25252FmTOR%252BKinase%252BInhibitor%26aulast%3DMallon%26aufirst%3DRobert%26date%3D2011%26date%3D2011%26volume%3D17%26issue%3D10%26spage%3D3193%26epage%3D3203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jo-Anne  Pinson</span>, <span class="hlFld-ContribAuthor ">Oleg  Schmidt-Kittler</span>, <span class="hlFld-ContribAuthor ">Jiuxiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Ian G.  Jennings</span>, <span class="hlFld-ContribAuthor ">Kenneth W.  Kinzler</span>, <span class="hlFld-ContribAuthor ">Bert  Vogelstein</span>, <span class="hlFld-ContribAuthor ">David K.  Chalmers</span>, <span class="hlFld-ContribAuthor ">Philip E.  Thompson</span>. </span><span class="cited-content_cbyCitation_article-title">Thiazolidinedione-Based PI3Kα Inhibitors: An Analysis of Biochemical and Virtual Screening Methods. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2011,</strong> <em>6 </em>
                                    (3)
                                     , 514-522. <a href="https://doi.org/10.1002/cmdc.201000467" title="DOI URL">https://doi.org/10.1002/cmdc.201000467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201000467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201000467%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DThiazolidinedione-Based%252BPI3K%2525CE%2525B1%252BInhibitors%25253A%252BAn%252BAnalysis%252Bof%252BBiochemical%252Band%252BVirtual%252BScreening%252BMethods%26aulast%3DPinson%26aufirst%3DJo-Anne%26date%3D2011%26date%3D2011%26volume%3D6%26issue%3D3%26spage%3D514%26epage%3D522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aranapakam M.  Venkatesan</span>, <span class="hlFld-ContribAuthor ">Zecheng  Chen</span>, <span class="hlFld-ContribAuthor ">Osvaldo Dos  Santos</span>, <span class="hlFld-ContribAuthor ">Christoph  Dehnhardt</span>, <span class="hlFld-ContribAuthor ">Efren Delos  Santos</span>, <span class="hlFld-ContribAuthor ">Semiramis  Ayral-Kaloustian</span>, <span class="hlFld-ContribAuthor ">Robert  Mallon</span>, <span class="hlFld-ContribAuthor ">Irwin  Hollander</span>, <span class="hlFld-ContribAuthor ">Larry  Feldberg</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Ker  Yu</span>, <span class="hlFld-ContribAuthor ">Inder  Chaudhary</span>, <span class="hlFld-ContribAuthor ">Tarek S.  Mansour</span>. </span><span class="cited-content_cbyCitation_article-title">PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (19)
                                     , 5869-5873. <a href="https://doi.org/10.1016/j.bmcl.2010.07.104" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.07.104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.07.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.07.104%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPKI-179%25253A%252BAn%252Borally%252Befficacious%252Bdual%252Bphosphatidylinositol-3-kinase%252B%252528PI3K%252529%25252Fmammalian%252Btarget%252Bof%252Brapamycin%252B%252528mTOR%252529%252Binhibitor%26aulast%3DVenkatesan%26aufirst%3DAranapakam%2BM.%26date%3D2010%26volume%3D20%26issue%3D19%26spage%3D5869%26epage%3D5873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven T.  Staben</span>, <span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>, <span class="hlFld-ContribAuthor ">Daniel P.  Sutherlin</span>, <span class="hlFld-ContribAuthor ">Seema R.  Bhat</span>, <span class="hlFld-ContribAuthor ">Georgette M.  Castanedo</span>, <span class="hlFld-ContribAuthor ">Irina S.  Chuckowree</span>, <span class="hlFld-ContribAuthor ">Jenna  Dotson</span>, <span class="hlFld-ContribAuthor ">Adrian J.  Folkes</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, <span class="hlFld-ContribAuthor ">Leslie  Lee</span>, <span class="hlFld-ContribAuthor ">John  Lesnick</span>, <span class="hlFld-ContribAuthor ">Cristina  Lewis</span>, <span class="hlFld-ContribAuthor ">Jeremy M.  Murray</span>, <span class="hlFld-ContribAuthor ">Jim  Nonomiya</span>, <span class="hlFld-ContribAuthor ">Alan G.  Olivero</span>, <span class="hlFld-ContribAuthor ">Emile  Plise</span>, <span class="hlFld-ContribAuthor ">Jodie  Pang</span>, <span class="hlFld-ContribAuthor ">Wei Wei  Prior</span>, <span class="hlFld-ContribAuthor ">Laurent  Salphati</span>, <span class="hlFld-ContribAuthor ">Lionel  Rouge</span>, <span class="hlFld-ContribAuthor ">Deepak  Sampath</span>, <span class="hlFld-ContribAuthor ">Vickie  Tsui</span>, <span class="hlFld-ContribAuthor ">Nan Chi  Wan</span>, <span class="hlFld-ContribAuthor ">Shumei  Wang</span>, <span class="hlFld-ContribAuthor ">Christian  Weismann</span>, <span class="hlFld-ContribAuthor ">Ping  Wu</span>, <span class="hlFld-ContribAuthor ">Bing-Yan  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (20)
                                     , 6048-6051. <a href="https://doi.org/10.1016/j.bmcl.2010.08.067" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.08.067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.08.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.08.067%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-based%252Boptimization%252Bof%252Bpyrazolo-pyrimidine%252Band%252B-pyridine%252Binhibitors%252Bof%252BPI3-kinase%26aulast%3DStaben%26aufirst%3DSteven%2BT.%26date%3D2010%26volume%3D20%26issue%3D20%26spage%3D6048%26epage%3D6051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abhijit  Roychowdhury</span>, <span class="hlFld-ContribAuthor ">Rajiv  Sharma</span>, <span class="hlFld-ContribAuthor ">Sanjay  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the discovery of small molecule mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2010,</strong> <em>2 </em>
                                    (10)
                                     , 1577-1589. <a href="https://doi.org/10.4155/fmc.10.233" title="DOI URL">https://doi.org/10.4155/fmc.10.233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.10.233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.10.233%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bdiscovery%252Bof%252Bsmall%252Bmolecule%252BmTOR%252Binhibitors%26aulast%3DRoychowdhury%26aufirst%3DAbhijit%26date%3D2010%26volume%3D2%26issue%3D10%26spage%3D1577%26epage%3D1589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sébastien  Albert</span>, <span class="hlFld-ContribAuthor ">Maria  Serova</span>, <span class="hlFld-ContribAuthor ">Chantal  Dreyer</span>, <span class="hlFld-ContribAuthor ">Marie-Paule  Sablin</span>, <span class="hlFld-ContribAuthor ">Sandrine  Faivre</span>, <span class="hlFld-ContribAuthor ">Eric  Raymond</span>. </span><span class="cited-content_cbyCitation_article-title">New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2010,</strong> <em>19 </em>
                                    (8)
                                     , 919-930. <a href="https://doi.org/10.1517/13543784.2010.499121" title="DOI URL">https://doi.org/10.1517/13543784.2010.499121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543784.2010.499121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543784.2010.499121%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DNew%252Binhibitors%252Bof%252Bthe%252Bmammalian%252Btarget%252Bof%252Brapamycin%252Bsignaling%252Bpathway%252Bfor%252Bcancer%26aulast%3DAlbert%26aufirst%3DS%25C3%25A9bastien%26date%3D2010%26date%3D2010%26volume%3D19%26issue%3D8%26spage%3D919%26epage%3D930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Zhang</span>, <span class="hlFld-ContribAuthor ">Semiramis  Ayral-Kaloustian</span>, <span class="hlFld-ContribAuthor ">James T.  Anderson</span>, <span class="hlFld-ContribAuthor ">Thai  Nguyen</span>, <span class="hlFld-ContribAuthor ">Sasmita  Das</span>, <span class="hlFld-ContribAuthor ">Aranapakam M.  Venkatesan</span>, <span class="hlFld-ContribAuthor ">Natasja  Brooijmans</span>, <span class="hlFld-ContribAuthor ">Judy  Lucas</span>, <span class="hlFld-ContribAuthor ">Ker  Yu</span>, <span class="hlFld-ContribAuthor ">Irwin  Hollander</span>, <span class="hlFld-ContribAuthor ">Robert  Mallon</span>. </span><span class="cited-content_cbyCitation_article-title">5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-α and mTOR for the treatment of breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (12)
                                     , 3526-3529. <a href="https://doi.org/10.1016/j.bmcl.2010.04.139" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.04.139</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.04.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.04.139%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D5-Ureidobenzofuranone%252Bindoles%252Bas%252Bpotent%252Band%252Befficacious%252Binhibitors%252Bof%252BPI3%252Bkinase-%2525CE%2525B1%252Band%252BmTOR%252Bfor%252Bthe%252Btreatment%252Bof%252Bbreast%252Bcancer%26aulast%3DZhang%26aufirst%3DNan%26date%3D2010%26volume%3D20%26issue%3D12%26spage%3D3526%26epage%3D3529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David J.  Richard</span>, <span class="hlFld-ContribAuthor ">Jeroen C.  Verheijen</span>, <span class="hlFld-ContribAuthor ">Ker  Yu</span>, <span class="hlFld-ContribAuthor ">Arie  Zask</span>. </span><span class="cited-content_cbyCitation_article-title">Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kα. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (8)
                                     , 2654-2657. <a href="https://doi.org/10.1016/j.bmcl.2010.02.029" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.02.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.02.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DTriazines%252Bincorporating%252B%252528R%252529-3-methylmorpholine%252Bare%252Bpotent%252Binhibitors%252Bof%252Bthe%252Bmammalian%252Btarget%252Bof%252Brapamycin%252B%252528mTOR%252529%252Bwith%252Bselectivity%252Bover%252BPI3K%2525CE%2525B1%26aulast%3DRichard%26aufirst%3DDavid%2BJ.%26date%3D2010%26volume%3D20%26issue%3D8%26spage%3D2654%26epage%3D2657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of known PI3K inhibitors (<b>1</b> and <b>2</b>) and of novel compound <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure and biological profile of initial discovery lead <b>4</b> and the triazolopyrimidine lead <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Triazolopyrimidine <b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) POCl<sub>3</sub>, Me<sub>2</sub>NC<sub>6</sub>H<sub>5</sub>, <i>T</i> < 30 °C, 13%; (b) NEt<sub>3</sub>, morpholine, 0 °C, 92%; (c) 4-amino-1-benzylpiperidine, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 78%; (d) Raney Ni, MeOH, N<sub>2</sub>H<sub>4</sub>, 63%; (e) NaNO<sub>2</sub>, AcOH, 0 °C, 54%; (f) (Ph<sub>3</sub>P)<sub>4</sub>Pd, 3-hydroxymethylphenylboronic acid, Na<sub>2</sub>CO<sub>3</sub>, DME, 140 °C, 1 h microwave, 45%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i>-3-Alkyl-2-arylureidotriazolopyrimidines <b>14</b>−<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-aminophenylboronic acid pinacol ester, (Ph<sub>3</sub>P)<sub>4</sub>Pd, Na<sub>2</sub>CO<sub>3</sub>, DME, 140 °C, 1 h, microwave, 57%; (b) triphosgene, R<sub>2</sub>NH<sub>2</sub>, Et<sub>3</sub>N, THF or R<sub>2</sub>NCO, THF.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 4-Benzamidoureido Analogues <b>3</b> and <b>32</b>−<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOH, THF, H<sub>2</sub>O, 85%; (b) HOBT, EDCI (or HBTU), Et<sub>3</sub>N, RR′NH, THF.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Modeling studies of analogue <b>27</b> docked in a homology model of PI3Kα, based on PI3Kγ crystal structures.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo biomarker analysis of <b>35</b> given at 50 mpk (iv) to MDA-361 tumor bearing nude mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vivo biomarker analysis at 8 h after <b>3</b> was administered at 25, 50, and 100 mpk (iv) to MDA-361 tumor bearing nude mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/medium/jm-2009-014982_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor efficacy of <b>3</b> in the MDA-361 (breast, Her2+/PIK3CA mutant) xenograft model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm9014982/production/images/large/jm-2009-014982_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9014982&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 17 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Targeting PI3K signaling in cancer: opportunities, challenges and limitations</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm9014982&amp;key=10.1038%2Fnrc2664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm9014982&amp;key=19629070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm9014982&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFylsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=550-562&author=J.+A.+Engelman&title=Targeting+PI3K+signaling+in+cancer%3A+opportunities%2C+challenges+and+limitations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K signalling in cancer: opportunities, challenges and limitations</span></div><div class="casAuthors">Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">550-562</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There are ample genetic and lab. studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells.  Inhibitors targeting this pathway are entering the clinic at a rapid pace.  In this Review, the therapeutic potential of drugs targeting PI3K-Akt signaling for the treatment of cancer is discussed.  I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCwdUnGEC20LVg90H21EOLACvtfcHk0ljHZUVv-ly1gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFylsrg%253D&md5=f0d4cc1fabf879e95f8b76e48cc9c1ad</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2664%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DTargeting%2520PI3K%2520signaling%2520in%2520cancer%253A%2520opportunities%252C%2520challenges%2520and%2520limitations%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D550%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Shaw, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">Ras, PI(3)K and mTOR signaling controls tumor cell growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">441</span><span class="NLM_x">, </span> <span class="NLM_fpage">424</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2006&pages=424-430&author=R.+J.+Shawauthor=L.+C.+Cantley&title=Ras%2C+PI%283%29K+and+mTOR+signaling+controls+tumor+cell+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DR.%2BJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DRas%252C%2520PI%25283%2529K%2520and%2520mTOR%2520signaling%2520controls%2520tumor%2520cell%2520growth%26jtitle%3DNature%26date%3D2006%26volume%3D441%26spage%3D424%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Stauffer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Imidazo[4,5-<i>c</i>]quinolines as inhibitors of the PI3K/PKB-pathway</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1027</span><span class="NLM_x">–</span> <span class="NLM_lpage">1030</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1027-1030&author=F.+Staufferauthor=S.+M.+Mairaauthor=P.+Furetauthor=C.+Garcia-Echeverria&title=Imidazo%5B4%2C5-c%5Dquinolines+as+inhibitors+of+the+PI3K%2FPKB-pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DImidazo%255B4%252C5-c%255Dquinolines%2520as%2520inhibitors%2520of%2520the%2520PI3K%252FPKB-pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1027%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brachmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chene, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pover, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schemaker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1851</span><span class="NLM_x">–</span> <span class="NLM_lpage">1863</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm9014982&amp;key=10.1158%2F1535-7163.MCT-08-0017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm9014982&amp;key=18606717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm9014982&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1851-1863&author=S.+M.+Mairaauthor=F.+Staufferauthor=J.+Brueggenauthor=P.+Furetauthor=C.+Schnellauthor=C.+Fritschauthor=S.+Brachmannauthor=P.+Cheneauthor=A.+De+Poverauthor=K.+Schemakerauthor=D.+Fabbroauthor=D.+Gabrielauthor=M.+Simonenauthor=L.+Murphyauthor=P.+Finanauthor=W.+Sellersauthor=C.+Garcia-Echeverria&title=Identification+and+characterization+of+NVP-BEZ235%2C+a+new+orally+available+dual+phosphatidylinositol+3-kinase%2Fmammalian+target+of+rapamycin+inhibitor+with+potent+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span></div><div class="casAuthors">Maira, Sauveur-Michel; Stauffer, Frederic; Brueggen, Josef; Furet, Pascal; Schnell, Christian; Fritsch, Christine; Brachmann, Saskia; Chene, Patrick; De Pover, Alain; Schoemaker, Kevin; Fabbro, Doriano; Gabriel, Daniela; Simonen, Marjo; Murphy, Leon; Finan, Peter; Sellers, William; Garcia-Echeverria, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1851-1863</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells, providing unique opportunities for anticancer therapeutic intervention.  NVP-BEZ235 is an imidazo[4,5-c]quinoline deriv. that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes.  In cellular settings using human tumor cell lines, this mol. is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest.  The cellular activity of NVP-BEZ235 translates well in in vivo models of human cancer.  Thus, the compd. was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies.  Ex vivo pharmacokinetic/pharmacodynamic analyses of tumor tissues showed a time-dependent correlation between compd. concn. and PI3K/Akt pathway inhibition.  Collectively, the preclin. data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties.  NVP-BEZ235 is currently in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyO784qv52vrVg90H21EOLACvtfcHk0ljHZUVv-ly1gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D&md5=5b1979e134dd12065198d86dbc11ce15</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0017%26sid%3Dliteratum%253Aachs%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBrachmann%26aufirst%3DS.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DSchemaker%26aufirst%3DK.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGabriel%26aufirst%3DD.%26aulast%3DSimonen%26aufirst%3DM.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DSellers%26aufirst%3DW.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520NVP-BEZ235%252C%2520a%2520new%2520orally%2520available%2520dual%2520phosphatidylinositol%25203-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitor%2520with%2520potent%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1851%26epage%3D1863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Gibbons, J.; Abraham, R.; Dehnhardt, C. M.; Venkatesan, A. M.; Delos Santos, E.; Chen, Z.; Santos, O.; Ayral-Kaloustain, S.; Brooijmans, N.; Mansour, T. S.</span><span> </span><span class="NLM_article-title">PKI-402, a Dual PI3K/mTOR Inhibitor</span>.  <span class="citation_source-book">Molecular Targets and Cancer Therapeutics</span>, Boston, MA, Nov 15−19, 2009; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Abstract B142.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Mallon&author=I.+Hollander&author=L.+Feldberg&author=J.+Lucas&author=J.+Gibbons&author=R.+Abraham&author=C.+M.+Dehnhardt&author=A.+M.+Venkatesan&author=E.+Delos+Santos&author=Z.+Chen&author=O.+Santos&author=S.+Ayral-Kaloustain&author=N.+Brooijmans&author=T.+S.+Mansour&title=Molecular+Targets+and+Cancer+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMallon%26aufirst%3DR.%26atitle%3DPKI-402%252C%2520a%2520Dual%2520PI3K%252FmTOR%2520Inhibitor%26btitle%3DMolecular%2520Targets%2520and%2520Cancer%2520Therapeutics%26pub%3DAACR%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The identification of 2-(1<i>H</i>-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine(GDC 0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+S.+Pangauthor=G.+Patelauthor=H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H+Ultschauthor=M.+Valentiauthor=+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+identification+of+2-%281H-indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine%28GDC+0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%2BS.%26aulast%3DPatel%26aufirst%3DG.%26aulast%3DPergl-Wilson%26aufirst%3DH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520identification%2520of%25202-%25281H-indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2528GDC%25200941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Hayakawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritomo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koizumi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, P.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-<i>d</i>]pyrimidine derivatives as novel PI3 kinase p110α inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2438</span><span class="NLM_x">–</span> <span class="NLM_lpage">2442</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2438-2442&author=M.+Hayakawaauthor=H.+Kaizawaauthor=H.+Moritomoauthor=T.+Koizumiauthor=T.+Ohishiauthor=M.+Yamanoauthor=M.+Okadaauthor=M.+Ohtaauthor=S.+Tsukamotoauthor=F.+I+Raynaudauthor=P.+Workmanauthor=M.+D.+Waterfieldauthor=P.+Parker&title=Synthesis+and+biological+evaluation+of+pyrido%5B3%E2%80%B2%2C2%E2%80%B2%3A4%2C5%5Dfuro%5B3%2C2-d%5Dpyrimidine+derivatives+as+novel+PI3+kinase+p110%CE%B1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHayakawa%26aufirst%3DM.%26aulast%3DKaizawa%26aufirst%3DH.%26aulast%3DMoritomo%26aufirst%3DH.%26aulast%3DKoizumi%26aufirst%3DT.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DYamano%26aufirst%3DM.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DParker%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520pyrido%255B3%25E2%2580%25B2%252C2%25E2%2580%25B2%253A4%252C5%255Dfuro%255B3%252C2-d%255Dpyrimidine%2520derivatives%2520as%2520novel%2520PI3%2520kinase%2520p110%25CE%25B1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2438%26epage%3D2442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Dehnhardt, C. M.; Venkatesan, A. M.; Chen, Z.; Delos Santos, E.; Santos, O.; Bursavich, M.; Brooijmans, B.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Ayral-Kaloustian, S.; Gibbons, J.; Abraham, R.; Mansour, T. S.</span><span> </span><span class="NLM_article-title">Novel Imidazolopyrimidines as Dual PI3-Kinase/mTor Inhibitors</span>.  <span class="citation_source-book">Proceedings of the 100th Annual Meeting of the American Association for Cancer Research</span>, Denver, CO, Apr 18−22, 2009; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Abstract 2017.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=C.+M.+Dehnhardt&author=A.+M.+Venkatesan&author=Z.+Chen&author=E.+Delos+Santos&author=O.+Santos&author=M.+Bursavich&author=B.+Brooijmans&author=R.+Mallon&author=I.+Hollander&author=L.+Feldberg&author=J.+Lucas&author=K.+S.+Yu+Ayral-Kaloustian&author=J.+Gibbons&author=R.+Abraham&author=T.+S.+Mansour&title=Proceedings+of+the+100th+Annual+Meeting+of+the+American+Association+for+Cancer+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDehnhardt%26aufirst%3DC.%2BM.%26atitle%3DNovel%2520Imidazolopyrimidines%2520as%2520Dual%2520PI3-Kinase%252FmTor%2520Inhibitors%26btitle%3DProceedings%2520of%2520the%2520100th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%26pub%3DAACR%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Chen, Z.; Venkatesan, A. M.; Dehndardt, C. M.; Ayral-Kaloustian, S.; Mansour, T. S.; Brooijmans, N.; Mallon, R.; Hollander, I.; Yu, K.</span><span> </span><span class="NLM_article-title">Discovery of Novel Pyrrolo[3,2-<i>d</i>]pyrimidine Derivatives as PI3-Kinase Inhibitors</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 238th National Meeting of the American Chemical Society, Washington, DC, Aug 16−20, 2009; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=Z.+Chen&author=A.+M.+Venkatesan&author=C.+M.+Dehndardt&author=S.+Ayral-Kaloustian&author=T.+S.+Mansour&author=N.+Brooijmans&author=R.+Mallon&author=I.+Hollander&author=K.+Yu&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Novel%2520Pyrrolo%255B3%252C2-d%255Dpyrimidine%2520Derivatives%2520as%2520PI3-Kinase%2520Inhibitors%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verheijen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malwitz, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svenson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5013</span><span class="NLM_x">–</span> <span class="NLM_lpage">5016</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900851f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5013-5016&author=A.+Zaskauthor=J.+C.+Verheijenauthor=K.+Curranauthor=J.+Kaplanauthor=D.+J.+Richardauthor=P.+Nowakauthor=D.+J.+Malwitzauthor=N.+Brooijmansauthor=J.+Bardauthor=K.+Svensonauthor=J.+Lucasauthor=L.+Toral-Barzaauthor=W.+Zhangauthor=I.+Hollanderauthor=J.+J.+gibbonsauthor=R.+T.+Abrahamauthor=S.+Ayral-Kaloustianauthor=T.+S.+Mansourauthor=K.+Yu&title=ATP-competitive+inhibitors+of+the+mammalian+target+of+rapamycin%3A+design+and+synthesis+of+highly+potent+and+selective+pyrazolopyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm900851f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900851f%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DMalwitz%26aufirst%3DD.%2BJ.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DSvenson%26aufirst%3DK.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3Dgibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DATP-competitive%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%253A%2520design%2520and%2520synthesis%2520of%2520highly%2520potent%2520and%2520selective%2520pyrazolopyrimidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5013%26epage%3D5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Fan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mostov, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span> </span><span class="NLM_article-title">A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=341-349&author=Q.+Fanauthor=Z.+A.+Knightauthor=D.+D.+Goldenbergauthor=W.+Yuauthor=K.+E.+Mostovauthor=D.+Stokoeauthor=K.+M.+Shokatauthor=W.+A.+Weiss&title=A+dual+PI3+kinase%2FmTOR+inhibitor+reveals+emergent+efficacy+in+glioma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DQ.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DMostov%26aufirst%3DK.%2BE.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26atitle%3DA%2520dual%2520PI3%2520kinase%252FmTOR%2520inhibitor%2520reveals%2520emergent%2520efficacy%2520in%2520glioma%26jtitle%3DCancer%2520Cell%26date%3D2006%26volume%3D9%26spage%3D341%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Gillman, H.; Blatt, H.</span> <span class="citation_source-book">Organic Syntheses</span>; Wiley & Sons: New York,<span class="NLM_x"> </span><span class="NLM_year">1943</span><span class="NLM_x">; </span>Collect. Vol.  <span class="NLM_volume">II</span>, p  <span class="NLM_fpage">440</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1943&pages=440&author=H.+Gillman&author=H.+Blatt&title=Organic+Syntheses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGillman%26aufirst%3DH.%26btitle%3DOrganic%2520Syntheses%26date%3D1943%26volume%3DII%26spage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Robins, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dille, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, B. E.</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1954</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">933</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo01371a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Robins%2C+R.+K.%3B+Dille%2C+K.+L.%3B+Christensen%2C+B.+E.J.+Org.+Chem.+1954%2C+19%2C+930%E2%80%93933"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjo01371a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01371a010%26sid%3Dliteratum%253Aachs%26aulast%3DRobins%26aufirst%3DR.%2BK.%26aulast%3DDille%26aufirst%3DK.%2BL.%26aulast%3DChristensen%26aufirst%3DB.%2BE.%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1954%26volume%3D19%26spage%3D930%26epage%3D933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Fukskovka, K.; Halishek, L.; Krystof, V.; Lenobel, R.; Strnad, M.</span> PCT Int. Patent. Appl. WO2004/018473,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Fukskovka%2C+K.%3B+Halishek%2C+L.%3B+Krystof%2C+V.%3B+Lenobel%2C+R.%3B+Strnad%2C+M.+PCT+Int.+Patent.+Appl.+WO2004%2F018473%2C+2004."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFukskovka%26aufirst%3DK.%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, S. F.</span><span> </span><span class="NLM_article-title">A directly labeled TR-FRET assay for monitoring phosphoinositide-3-kinase activity</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm9014982&amp;key=10.2174%2F138620706777935360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm9014982&amp;key=16925516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm9014982&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVKrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=565-570&author=X.+Yangauthor=P.+Liauthor=L.+Feldbergauthor=S.+C.+Kimauthor=M.+Bowmanauthor=I.+Hollanderauthor=R.+Mallonauthor=S.+F.+Wolf&title=A+directly+labeled+TR-FRET+assay+for+monitoring+phosphoinositide-3-kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A directly labeled TR-FRET assay for monitoring phosphoinositide-3-kinase activity</span></div><div class="casAuthors">Yang, Xiaoke; Li, Puyao; Feldberg, Larry; Kim, Steven C.; Bowman, Michael; Hollander, Irwin; Mallon, Robert; Wolf, Stanley F.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">565-570</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3Ks) comprise a family of kinases that transfer the terminal phosphate of ATP to phosphoinositides at the 3-hydroxyl of the inositol ring to form phosphoinositide (3,4,5)-triphosphate (PIP3).  The PI3Ks have been shown to play key roles in cell growth, motility, morphol., and survival and thus are of interest as targets in anti-inflammatory and anti-oncogenic drug development.  To facilitate identification of novel and selective inhibitors of PI3Ks, we have developed a TR-FRET assay that uses directly labeled reagents.  The assay makes use of the high affinity binding of phosphoinositides to a pleckstrin homol. (PH) domain in the general receptor for phosphoinositides 1 (Grp1) protein.  It monitors PIP3 produced from the enzymic reaction by measuring its competition with Bodipy-FL-labeled PIP3 for binding to terbium chelate-labeled Grp1.  By using directly labeled reagents, this assay configuration offers higher sensitivity and faster binding/dissocn. kinetics than existing non-radioactive assays, which are crit. for competitive assay formats.  The assay is homogeneous, robust (Z' = 0.88), and simple and, thus, compatible with high throughput screening (HTS) processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3gMlKxLJcJLVg90H21EOLACvtfcHk0lit7WP2XtYJ_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVKrtb0%253D&md5=def2c27a291077edddd2047918779826</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F138620706777935360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620706777935360%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BC.%26aulast%3DBowman%26aufirst%3DM.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DWolf%26aufirst%3DS.%2BF.%26atitle%3DA%2520directly%2520labeled%2520TR-FRET%2520assay%2520for%2520monitoring%2520phosphoinositide-3-kinase%2520activity%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2006%26volume%3D9%26spage%3D565%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Olivero, A. G.; Heffron, T.; Berry, L.; Berry, M.; Castanedo, G.; Chang, C.; Dotson, J.; Friedman, L. S.; Goldsmith, R.; Lesnick, J.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Pang, J.; Peterson, D.; Prior, W. W.; Salphati, L.; Sampath, D.; Sutherlin, D.; Tsui, V.; Ultsch, M.; Wang, S.; Wiesmann, C.; Wong, S.; Zhu, B.-Y.; Chuckowree, I.; Folkes, A.; Shuttleworth, S.</span><span> </span><span class="NLM_article-title">Design and synthesis of dual PI3K/mTOR Inhibitors</span>.  <span class="citation_source-book">Proceedings of the 100th Annual Meeting of the American Association for Cancer Research</span>, Denver, CO, Apr 18−22, 2009; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Abstract 2707.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+G.+Olivero&author=T.+Heffron&author=L.+Berry&author=M.+Berry&author=G.+Castanedo&author=C.+Chang&author=J.+Dotson&author=L.+S.+Friedman&author=R.+Goldsmith&author=J.+Lesnick&author=C.+Lewis&author=S.+Mathieu&author=J.+Nonomiya&author=J.+Pang&author=D.+Peterson&author=W.+W.+Prior&author=L.+Salphati&author=D.+Sampath&author=D.+Sutherlin&author=V.+Tsui&author=M.+Ultsch&author=S.+Wang&author=C.+Wiesmann&author=S.+Wong&author=B.-Y.+Zhu&author=I.+Chuckowree&author=A.+Folkes&author=S.+Shuttleworth&title=Proceedings+of+the+100th+Annual+Meeting+of+the+American+Association+for+Cancer+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual%2520PI3K%252FmTOR%2520Inhibitors%26btitle%3DProceedings%2520of%2520the%2520100th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%26pub%3DAACR%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Golas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm9014982&amp;key=12543790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm9014982&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Krsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=375-381&author=J.+M.+Golasauthor=K.+Arndtauthor=C.+Etienneauthor=J.+Lucasauthor=D.+Nardinauthor=J.+Gibbonsauthor=P.+Frostauthor=F.+Yeauthor=D.+H.+Boschelliauthor=F.+Boschelli&title=SKI-606%2C+a+4-anilino-3-quinolinecarbonitrile+dual+inhibitor+of+Src+and+Abl+kinases%2C+is+a+potent+antiproliferative+agent+against+chronic+myelogenous+leukemia+cells+in+culture+and+causes+regression+of+K562+xenografts+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice</span></div><div class="casAuthors">Golas, Jennifer M.; Arndt, Kim; Etienne, Carlo; Lucas, Judy; Nardin, Danielle; Gibbons, James; Frost, Philip; Ye, Fei; Boschelli, Diane H.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">375-381</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive tyrosine kinase activity of Bcr-Abl promotes proliferation and survival of chronic myelogenous leukemia (CML) cells.  Inhibition of Bcr-Abl tyrosine kinase activity or signaling proteins activated by Bcr-Abl in CML cells blocks proliferation and causes apoptotic cell death.  The selective Abl kinase inhibitor, STI-571 (marketed as Gleevec), is toxic to CML cells in culture, causes regression of CML tumors in nude mice, and is currently used to treat CML patients.  Here we describe a p.o. active, dual Src/Abl kinase inhibitor with potent antiproliferative activity against CML cells in culture.  This 4-anilino-3-quinolinecarbonitrile (SKI-606) ablates tyrosine phosphorylation of Bcr-Abl in CML cells and of v-Abl expressed in fibroblasts.  SKI-606 inhibits phosphorylation of cellular proteins, including STAT5, at concns. that inhibit proliferation in CML cells.  Phosphorylation of the autoactivation site of the Src family kinases Lyn and/or Hck is also reduced by treatment with SKI-606.  Once daily oral administration of this compd. at 100 mg/kg for 5 days causes complete regression of large K562 xenografts in nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ0DM9Z0QjjLVg90H21EOLACvtfcHk0ljkSdJrlDXTMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Krsg%253D%253D&md5=e7b5e5ffee0238543dc9c31b7e86b3d2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGolas%26aufirst%3DJ.%2BM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DNardin%26aufirst%3DD.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DSKI-606%252C%2520a%25204-anilino-3-quinolinecarbonitrile%2520dual%2520inhibitor%2520of%2520Src%2520and%2520Abl%2520kinases%252C%2520is%2520a%2520potent%2520antiproliferative%2520agent%2520against%2520chronic%2520myelogenous%2520leukemia%2520cells%2520in%2520culture%2520and%2520causes%2520regression%2520of%2520K562%2520xenografts%2520in%2520nude%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D375%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm9014982&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm9014982%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-2" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm9014982" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67990e13ffab3ce8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
